













The synthesis of star copolymers for the delivery of 





The synthesis of star copolymers for the delivery 
of macromolecular guest & photodynamic therapy 
 
Alaa Fadhil Kadhim 
A thesis submitted for the degree of Doctor 
of philosophy  
Department of Chemistry 
The University of Sheffield 







To Mum and Dad,  




I would like to express my sincere gratitude to Dr. Lance Twyman for his guidance in all the 
time of my research and writing up. I could not have imagined having a better supervisor for 
my Ph.D study. 
As a part of my scholarship, I had the opportunity to travel to Singapore working with 
carcinoma cells. This would not be possible without the help and guidance I have received 
from Dr. Haishan Wang, my sincere thanks also goes to him. Special thanks go to Dr. Helen 
Bryant and Luke Mckenzie, who have accepted to collaborate with us and completed the cell 
works. Without their precious support it would not be possible to conduct this research. 
To my group members-Azrah, Abdullah, Bunian, Devanshi, Fatema, Greg, Hamza, Ibrahim, 
Jawad, Mang, Saimra and Talal- thanks for the stimulating discussions, and for all the fun we 
have had in the last four years. I would like to thank Heather, Nick, Peter, Simon and the 
department of Chemistry for providing the essential laboratory and technical support towards 
my research work.  
Last but not the least, I would like to thank my family: my parents and to my sisters and brother 




Table of Figures 
FIGURE 1.1: EXAMPLE FOR CONTROLLED DRUG DELIVERY.[7] ............................................................................................. 24 
FIGURE 1.2: CURVE OF DRUG CONCENTRATION IN PLASMA OVER TIME AFTER A SINGLE DOSE [16] ............................................... 25 
FIGURE 1.3: DRUG CONCENTRATIONS IN PLASMA AFTER DELIVERY BY CONVENTIONAL INJECTION IN A CHRONIC DISEASE[17] ............ 26 
FIGURE 1.4: POLYMER FUNCTIONALIZED TO INTERACT WITH SPECIFIC TARGETS [24-26] .............................................................. 27 
FIGURE 1.5: ENDOCYTOSIS IS THE PROCESS BY WHICH MOLECULES ENTER INTO CELLS. [30] FIRSTLY, THE CELL MEMBRANE FOLDS’ 
INWARDS RESULTS IN THE FORMATION OF A SMALL VESICLE CALLED ENDOSOME. THIS ENDOSOME THEN MERGES WITH A 
LYSOSOME AND FORMS A SECONDARY LYSOSOME, WHICH CONTAINS AN ACIDIC INTERNAL ENVIRONMENT WITH ENZYMES WHERE 
THE LINKER MOLECULES BREAK AND RELEASE THE DRUG. [31] ...................................................................................... 29 
FIGURE 1.6: SCHEMATIC REPRESENTATION SHOWING THE  ANATOMICAL AND PHYSIOLOGICAL CHARACTERISTICS OF HEALTHY AND 
MALIGNANT TISSUE IN TERM OF THE VASCULAR PERMEABILITY AND RETENTION OF SMALL AND LARGE MOLECULES (EPR EFFECT). 
[27] ................................................................................................................................................................. 31 
FIGURE 1.7:EXAMPLES OF COVALENT AND NON-COVALENT ENCAPSULATION [37] .................................................................... 32 
FIGURE 1.8: FREE SURFACTANT MOLECULES BELOW CMC (LEFT) AND ABOVE CMC FORMING A MICELLE (RIGHT) ....................... 33 
FIGURE 1.9: STEP GROWTH POLYCONDENSATION............................................................................................................. 36 
FIGURE 1.10:  SELF-CONDENSING VINYL POLYMERIZATION ................................................................................................ 36 
FIGURE 1.11: RING OPENING POLYMERIZATION ............................................................................................................... 37 
FIGURE 1.12: EXAMPLES OF PORPHYRIN (I-IV) AND NON-PORPHYRIN BASED PS SYSTEMS (V-VII) ............................................... 39 
FIGURE 1.13:CHEMICAL STRUCTURE OF PHOTOFRIN, A MIXTURE OF HEMATOPORPHYRIN DIMERS AND OLIGOMERS ...................... 40 
FIGURE 1.14: CHEMICAL STRUCTURE OF CHLORINE E6 ...................................................................................................... 41 
FIGURE 1.15: FORMATION OF PDT ROS THROUGH TYPE 1 AND 2 [62] ............................................................................... 42 
FIGURE 2.1: THE CHEMICAL STRUCTURE OF THE PORPHYRIN CORED HYPERBRANCHED POLYMER (HBP 15) AS A MACRO-GUEST ...... 49 
FIGURE 2.2: POSSIBLE SELF-ASSEMBLY OF PORPHYRIN-CORED STAR COPOLYMERS .................................................................. 50 
FIGURE 2.3: POTENTIAL PORPHYRIN DERIVATIVE TO BE USED AS A CORE IN DRUG DELIVERY SYSTEMS FOR PDT APPLICATIONS THPP 12 
AND TDHPP 13 ............................................................................................................................................... 51 
FIGURE 3.1: CHEMICAL STRUCTURE OF THE TRIMETHYLOLPROPANE 1,EPSILON-CAPROLACTONE 2 AND GLYCIDOL 3 SELECTED FOR THE 
PROPOSED COPOLYMERS. ................................................................................................................................... 54 
FIGURE 3.2:1H NMR SPECTRA OF SPCL60-HPG90 IN CDCL3 ............................................................................................. 57 
FIGURE 3.3:1H NMR SPECTRA OF SPCL60-HPG90 IN D2O ................................................................................................ 57 
6 
 
FIGURE 3.4: CMC DETERMINATION OF SPCL60-HPH90 .................................................................................................... 63 
FIGURE 3.5: CMC LEVEL OF TMP-HPG90 ..................................................................................................................... 64 
FIGURE 3.6: TREND TO SHOW THE INCREASE IN THE CONCENTRATION OF THE ENCAPSULATED HBP 11 WITHIN DIFFERENT SIZE OF STAR 
COPOLYMERS AND ONE CONTROL ......................................................................................................................... 70 
FIGURE 3.7: SCHEMATIC REPRESENTATION SHOWING WHERE THE ENCAPSULATION OF THE MACROMOLECULAR GUEST (TAPP-HBP 15) 
WITH A) HPG AND B) STAR COPOLYMER HAPPEN ..................................................................................................... 71 
FIGURE 4.1: POTENTIAL PORPHYRIN DERIVATIVE TO BE USED AS A CORE IN DRUG DELIVERY SYSTEMS FOR PDT APPLICATIONS THPP 12 
AND TDHPP 13 ............................................................................................................................................... 75 
FIGURE 4.2: DELOCALIZATION OF THE HYDROXYL LONE PAIR WITH THE AROMATICITY OF THE PORPHYRIN RING ............................. 84 
FIGURE 4.3: STRUCTURES OF S-THPP-HPG 28 AND S-TDHPP-HPG 29 ............................................................................ 88 
FIGURE 4.4: PLOTS OF THE HYDRODYNAMIC DIAMETER OBTAINED FOR VARIOUS CONCENTRATIONS OF A) S-THPP1-PCL40-HPG60 31, 
B) S-THPP-HPG 28 AND C) THPP-HPG IN DEIONISED WATER. ................................................................................ 94 
FIGURE 4.5: PLOTS OF THE INTENSITY RATIO OF I1/I3 AGAINST LOG CONCENTRATION OF A) SPPCL-HPG 41, B) S-THPP-HPG 31 AND 
C) THPP-HPG IN DEIONISED WATER. ................................................................................................................... 96 
FIGURE 4.6: % CELL VIABILITY OF THE PHOTOTOXICITY SRB ASSAY OF MCF-7 CELLS TREATED WITH DIFFERENT CONCENTRATIONS OF A) 
COMPOUND 41 AND B) COMPOUND 33 AT DIFFERENT LED DOSES OF ZERO (DARK), 5 MINUTES LED (0.84 J/CM2) AND 10 
MINUTES LED (1.65 J/CM2). .............................................................................................................................. 98 
FIGURE 4.7: % CELL VIABILITY OF THE DARK TOXICITY SRB FOR OF MCF-7 CELLS WITH AND WITHOUT REMOVAL OF THE MEDIA FOR 10 
MINUTES ......................................................................................................................................................... 99 
FIGURE 4.8: % CELL VIABILITY OF THE DARK TOXICITY SRB ASSAY OF MCF-7 CELLS TREATED WITH DIFFERENT CONCENTRATIONS OF A) 
COMPOUND 31 AND B) COMPOUND  33.............................................................................................................. 100 
FIGURE 4.9: PHOTOTOXICITY OF MCF-7 CELLS TREATED WITH DIFFERENT CONCENTRATIONS OF A) COMPOUND 31 AND B) COMPOUND 
33 ............................................................................................................................................................... 100 
FIGURE 4.10: GRAPH SHOWING THE DARK TOXICITY OF THE THPP-SET COMPOUNDS IN EJ CELLS AT 100 µM ........................... 101 
FIGURE 4.11: DARK TOXICITY OF THPP AT DIFFERENT CONCENTRATIONS IN EJ CELL LINE ...................................................... 102 
FIGURE 4.12: DARK TOXICITY OF TDHPP MOLECULE AND TDHPP-CORED POLYMER AT 100 µM ........................................... 103 
FIGURE 4.13: PHOTOTOXICITY OF THPP-SET COMPOUNDS USING EJ CELL LINE AT A LIGHT DOSE OF 10 MW/CM2 ..................... 103 
FIGURE 4.14: PHOTOTOXICITY OF TDHPP-SET COMPOUNDS USING EJ CELL LINE AT A LIGHT DOSE OF 10 MW/CM2 ................... 104 
FIGURE 5.1: THE CHEMICAL STRUCTURE OF PACLITAXEL .................................................................................................. 111 
7 
 
FIGURE 5.2: BEER LAMBERT PLOT OF PTX IN MEOH: PBS (3:7) ..................................................................................... 112 
FIGURE 5.3: PTX TOXICITY TO BLADDER CELL LINE AT DIFFERENT INCUBATION TIMES. ............................................................ 116 
FIGURE 5.4: STRUCTURE OF S-THPP1-PCL40-HPG60 31 ................................................................................................ 116 
FIGURE 5.5: TOXICITY OF DIFFERENT CONCENTRATIONS OF THE STAR COPOLYMER TO BLADDER CELL LINE (NO PTX ENCAPSULATION)
 ................................................................................................................................................................... 117 
FIGURE 5.6: CYTOTOXICITY OF PTX ENCAPSULATED WITH STAR COPOLYMER ....................................................................... 117 
FIGURE 5.7: STRUCTURE OF PTX INDICATING THE ELECTROPHILIC SITES .............................................................................. 118 
FIGURE 5.8: POSSIBLE PTX-MICELLE FORMATION .......................................................................................................... 119 
Table of Table  
TABLE 3.1: SUMMARY OF THE ESTIMATED MN VALUES BY GPC AND 1HNMR SPECTROSCOPY, AND THE EXPECTED MN OF THE 
HYDROPONIC SEGMENT OF STAR POLYMERS (SPCL) ................................................................................................. 58 
TABLE 3.2: SUMMARY OF THE ESTIMATED MN VALUES BY GPC AND 1H NMR, AND THE EXPECTED MN OF THE OF THE STAR CO-
POLYMERS  (SPCL-HPG) ................................................................................................................................... 59 
TABLE 3.3: MOLECULAR WEIGHT CHARACTERIZATION OF HPG POLYMERS ............................................................................ 62 
TABLE 3.4: TABLE SHOWING THE ENCAPSULATION OF TAPP-HBP 15 WITHIN THE HOST POLYMERS AT 10MG/ML ....................... 69 
TABLE 4.1: SUMMARY OF THE AVERAGE MOLECULAR WEIGHT OF PORPHYRIN-CORED POLYGLYCEROLS USING DIFFERENT TECHNIQUES
 ..................................................................................................................................................................... 81 
TABLE 4.2: SUMMARY OF THE AVERAGE MOLECULAR WEIGHT OF PORPHYRIN-CORED POLYGLYCEROLS USING DIFFERENT TECHNIQUES
 ..................................................................................................................................................................... 89 
TABLE 4.3: MOLECULAR WEIGHT OF THE INITIAL STAR POLYMERS DETERMINED BY DIFFERENT TECHNIQUES ................................. 89 
TABLE 4.4: MOLECULAR WEIGHT OF THE STAR COPOLYMERS DETERMINED BY DIFFERENT TECHNIQUES ....................................... 90 
TABLE 4.5: SUMMARY OF CMC LEVELS OBTAINED FOR POLYMERS AND THEIR DIAMETER AT THE CMC LEVEL .............................. 95 
TABLE 4.6: COMPOUNDS LABELLING ........................................................................................................................... 101 
TABLE 4.7: TABLE TO SHOW THE CONFOCAL IMAGES FOR NAKED PORPHYRIN (THPP (TH)), COMPOUND 1 (THPP-HPG), COMPOUND 
3 (S-THPP-HPG 33) AND COMPOUND 5 (SPPCL40-HPG60 41)............................................................................. 105 
TABLE 4.8: TABLE TO SHOW THE CONFOCAL IMAGES FOR NAKED PORPHYRIN (TDHPP (TD)), COMPOUND 2 (TDHPP-HPG), 
COMPOUND 4 (S-TDHPP-HPG 34) AND COMPOUND 5 (SPPCL10-HPG35 43) ......................................................... 106 
8 
 
TABLE 5.1: CHARACTERISATION OF PTX IN MEOH: PBS (3:7) ........................................................................................ 111 
TABLE 5.2: THERMODYNAMIC AND KINETIC SOLUBILITY OF PTX IN WATER ......................................................................... 113 





List of abbreviation  
Standard Abbreviations Standard Abbreviations 
13C NMR Carbon Nuclear Magnetic Resonance Spectroscopy 
Å   Angstrom 
ADME absorption, distribution, metabolism, excertion 
API Active pharmaceutical ingredients  
ATRP  Atom Transfer Radical Polymerisation 
CDD Controlled Drug Delivery  
CMC  Critical Micelle Concentration 
D2O  Deuterated Water 
d6 -DMSO  Deuterated Dimethyl Sulphoxide 
Da Dalton 
DB   Degree of Branching 
DCM   Dichloromethane 
DDS Drug Delivery System 
DLS  Dynamic Light Scattering 
DMF  Dimethylformamide 
EPR the enhanced permeability and retention  
ES-MS   Electrospray Ionisation Mass Spectrometry 
FDA Food and Drug Administration  
FT-IR  Fourier Transform Infrared Spectrophotometry 
GPC Gel Permeation Chromatography 
HBP  Hyperbranched Polymer 
10 
 
HMW  High Molecular Weight 
HPD Hematoporphyrin derivative  
HPG Hyperbranched polyglycerols 
K Kilo 
K2CO3  Potassium Carbonate 
LWM   Low Molecular Weight 
M Molar 
Mn  Number Average Molecular Weight 
mTHPC M-tetrahydroxophenyl chlorine  
MW Molecular Weight 
Mw Weight Average Molecular Weight 
nm Nanometre 
NPe6 Mono-L-aspartyl chlorine e6 
oC Degree Celsius 




PDI Polydispersity Index 
PDT Photodynamic therapy 
PEG Polyethylene Glycol 
PK Pharmacokinetics  
ppm  Part Per Million 
11 
 
PS Photosensitizers  
ROP  Ring Opening Polymerisation 
ROS Reactive oxygen species 
SEC  Size Exclusion Chromatography 
TDHPP Tetrakis(3.5-dihydroxyphenyl)-porphyrin  
TDMPP Tetrakis(3,5-dimethoxyphenyl)-porphyrin  
THF  Tetrahydrofuran 
THPP Tetrakis(4-hydroxyphenyl)-porphyrin  
TMP Trimethylolpropane  
UV/Vis  Ultraviolet-Visible Light Spectrophotometry 





ACKNOWLEDGMENTS .............................................................................................................................. 4 
List of abbreviation ..................................................................................................... 9 
Abstract ................................................................................................................... 16 
1. Introduction ..................................................................................................... 21 
1.1. NOVEL DRUG DELIVERY SYSTEM ........................................................................................................ 21 
1.1.1 Controlled Drug Release Method .................................................................................. 24 
1.1.2 Time-Controlled: Modified-Release Formulation .......................................................... 25 
1.1.3 Controlled Distribution .................................................................................................. 27 
1.1.4 The enhanced permeability and retention (EPR) effect ................................................ 29 
1.1.5 Drug encapsulation ....................................................................................................... 31 
1.1.6 Polymeric system: synthesis and application ................................................................ 32 
1.2 PHOTODYNAMIC THERAPY ........................................................................................................... 37 
1.2.1 Photosensitizers agents (PSs) ........................................................................................ 38 
1.2.2 Therapeutic irradiation ................................................................................................. 41 
1.2.3 Photophysics ................................................................................................................. 41 
1.2.4 Photochemistry ............................................................................................................. 42 
1.2.5 Mechanisms of cell death in PDT .................................................................................. 43 
1.2.6 Use of Nanoparticles ..................................................................................................... 44 
2. Aims and Objectives ....................................................................................... 46 
2.1 SYNTHESIS OF STAR COPOLYMERS FOR LARGE DRUG DELIVERY SYSTEM ................................................ 46 
2.1.1 General Design of the Proposed Drug Delivery System (Star Copolymers) and control 
systems 46 
2.1.2 Control system............................................................................................................... 48 
2.1.3 Testing the macro-encapsulation potential of the star copolymers ............................. 48 
2.2 PORPHYRIN-CORED STAR COPOLYMERS FOR PHOTODYNAMIC APPLICATION ......................................... 49 
2.3 CHEMO-PHOTODYNAMIC COMBINATION THERAPY ......................................................................... 51 
3. Synthesis of star copolymers for large drug delivery systems ........................ 53 
RESULT AND DISCUSSION ........................................................................... ERROR! BOOKMARK NOT DEFINED. 
3.1 SYNTHETIC CONSIDERATIONS ....................................................................................................... 53 
3.2 ONE-POT SYNTHESIS OF THE POLY (Ε-CAPROLACTONE)-B-POLYGLYCEROLS (PCL-HPG).......................... 54 
3.3 ANIONIC RING OPENING POLYMERIZATION OF FORMING POLY (E-CAPROLACTONE)................................ 55 
3.4 THE STRUCTURAL CHARACTERISATION OF SPCL-HPG AMPHIPHILIC COPOLYMERS ................................. 56 
3.5 ONE-POT SYNTHESIS OF HYPERBRANCHED POLYGLYCEROLS (HPG) ..................................................... 59 
3.6 CHARACTERISATION OF HYPERBRANCHED POLYGLYCEROLS ................................................................ 61 
3.7 AGGREGATION OF STAR COPOLYMERS ........................................................................................... 62 
3.8 SELECTION OF A SUITABLE MACROMOLECULAR GUEST ...................................................................... 64 
13 
 
3.9 THE SYNTHESIS OF A PORPHYRIN CORED FUNCTIONALIZED HBP (LARGE MOLECULE) .............................. 65 
3.10 ENCAPSULATION OF A LARGE HYDROPHOBIC MACROMOLECULAR ....................................................... 68 
3.11 SUMMARY ................................................................................................................................ 71 
4. Porphyrin cored star copolymers for photodynamic therapy ........................... 74 
RESULT AND DISCUSSUIO ........................................................................................................................ 74 
4.1 SYNTHESIS AND CHARACTERISATION OF PORPHYRIN PHOTOSENSITIZERS .............................................. 74 
4.1.1 Tetrakis(4-hydroxyphenyl)-porphyrin (THPP 12) ........................................................... 75 
4.1.2 Tetrakis(3, 5-dihydroxyphenyl)-porphyrin ..................................................................... 78 
4.2 SYNTHESIS OF PORPHYRIN-CORED HYPERBRANCHED POLYGLYCEROLS (HPG) ....................................... 80 
4.3 PORPHYRIN STAR POLY(Ɛ-CAPROLACTONE)-POLYGLYCEROL COPOLYMERS ........................................... 82 
4.4 SYNTHESIS OF PORPHYRIN INITIATORS ........................................................................................... 84 
4.4.1 Acetonide–porphyrin ..................................................................................................... 84 
4.4.2 Spacer–porphyrin (S-porphyrin) .................................................................................... 87 
4.4.3 SYNTHESIS OF SPACER–PORPHYRIN-CORED HYPERBRANCHED POLYGLYCEROLS .................................. 88 
4.5 SYNTHESIS OF PORPHYRIN STAR POLY(Ɛ-CAPROLACTONE)-POLYGLYCIDOL COPOLYMERS (SPPCL-HPG) .... 89 
4.6 MICELLE FORMULATION .............................................................................................................. 93 
4.6.1 Dynamic light scattering ............................................................................................... 93 
4.6.2 Fluorescence technique ................................................................................................. 95 
4.7 IN VITRO STUDY (CYTOTOXICITY AND PHOTOTOXICITY) ...................................................................... 97 
4.8 CELL WORK USING MCF-7 .......................................................................................................... 97 
4.9 MTT ASSAY USING EJ CELL LINES ................................................................................................ 101 
4.9.1 Intracellular localisation .............................................................................................. 104 
4.10 SUMMARY .............................................................................................................................. 107 
5.0 Chemo-Photodynamic Combination Therapy ............................................... 110 
5.1 Kinetic/Thermodynamic Solubility of PTX in water ...................................................... 112 
5.2 ENCAPSULATION OF PTX IN THE POLYMERIC MICELLES ................................................................... 113 
5.3 Encapsulation results ...................................................................................................... 114 
5.4 IN VITRO STUDY ....................................................................................................................... 115 
5.4.1 Control experiment to determine PTX toxicity to bladder cell line .............................. 115 
5.4.2 Polymer toxicity to bladder cell line .......................................................................... 116 
5.5 ENCAPSULATION OF PTX USING KINETIC METHOD ........................................................................ 121 
5.6 SUMMARY .............................................................................................................................. 123 
6.0 Conclusion and Further-work ....................................................................... 126 
7.0 Experimental  ............................................................................................... 130 
7.1 GENERAL CONSIDERATION ......................................................................................................... 130 
7.1.1 Reagents, solvents and general equipment ................................................................ 130 
7.1.2 Nuclear magnetic resonance spectroscopy ................................................................. 130 
7.1.3 UV-Vis Spectroscopy .................................................................................................... 130 
7.1.4 IR Spectroscopy ........................................................................................................... 130 
7.1.5 Thermal analysis ......................................................................................................... 131 
7.2 SYNTHESIS OF PORPHYRIN MOLECULES ........................................................................................ 131 
7.2.1 5,10,15,20-Tetrakis(4-hydroxyphenyl)-21H,23H-porphine (THPP 12) ........................ 131 
14 
 
7.2.2 Tetrakis (3, 5-dimethoxyphenyl)-21H, 23H-porphyrin (TDMPP 18) ............................ 132 
7.2.3 Tetrakis (3, 5-dihydroxyphenyl)-21H, 23H-porphyrin (TDHPP 13) .............................. 133 
7.3 SYNTHESIS OF PORPHYRIN INITIATOR ........................................................................................... 134 
7.3.1 Spacer-porphyrin (S-TDHPP 27)................................................................................... 134 
7.3.2 Spacer-porphyrin S-THPP 26 ....................................................................................... 135 
7.4 SYNTHESIS OF TAPP CORED POLY (3, 5-DIACETOXYBENZOIC ACID) 15 .............................................. 136 
7.4.1 Synthesis of 3, 5-diacetoxybenzoic acid (13) ............................................................... 136 
7.4.2 Synthesis of 4-acetoxybenzaldehyde (7).................................................................... 136 
7.5 SYNTHESIS OF TETRAKIS (4-DIACETOXYPHENYL)-21H, 23H-PORPHYRIN (TAPP 12) ........................... 137 
7.6 SYNTHESIS OF TAPP CORED POLY (3, 5-DIACETOXYBENZOIC ACID) (15) ............................................ 138 
7.7 GENERAL PROCEDURE FOR SYNTHESIS OF HYPERBRANCHED POLYGLYCEROL ....................................... 139 
7.7.1 Synthesis of trimethylolpropane (TMP) core hyperbranched polyglycerol ................. 140 
7.7.2 Synthesis of porphyrin core hyperbranched polyglycerol ........................................... 140 
7.7.3 Synthesis of (porphyrin with spacer) core hyperbranched polyglycerol .................. 141 
7.8 GENERAL PROCEDURE FOR SYNTHESIS OF AMPHIPHILIC COPOLYMERS BASED ON POLY(CAPROLACTONE) 
AND POLYGLYCEROLS ........................................................................................................................... 143 
7.8.1 Synthesis of trimethylolpropane (TMP) cored star poly (caprolactone)-block-
hyperbranched TMPPCL-b-HPG .................................................................................................. 144 
7.8.2 Synthesis of porphyrin cored star poly (caprolactone)-b-hyperbranched ................... 146 
7.9 CRITICAL AGGREGATION CONCENTRATION (CAC) .......................................................................... 148 
7.10 CELL CULTURE ......................................................................................................................... 148 
7.10.1 Imaging ....................................................................................................................... 149 
7.10.2 Light and dark toxicity – MTT assay ............................................................................ 149 









Traditional delivery systems use polymeric structures that contain internal voids or specific 
functionality that can be used to encapsulate smaller molecules, protecting them from external 
environments and delivering them to specific sites.  Although considerable success has been 
achieved in the delivery of small organic molecules, these systems are not suitable for the 
delivery of (larger) biomolecular drug moieties. This project has addressed this issue by 
constructing and studying nano-sized macromolecular carriers with the capacity to form and 
maintain a large volume of free internal space. A star polymeric core was synthesised to   
generate a suitable environment that can be used to encapsulate large macromolecular guest. 
The synthesis of the star copolymers involved a multi-step reaction process using a single pot 
procedure. Initially, a core functionalized with hydroxyl end groups (trimethylol propane TMP) 
was used as an initiator to ring open and polymerize caprolactone. The resulting hydrophobic 
star polymers (star poly(caprolactone) (SPCL)) which possessed a nucleophilic end group, 
were used to initiate a second ring opening polymerization (ROP) using a branched hydrophilic 
monomer (glycidol). Three star copolymers (SPCL-HPGs) were prepared with different chain 
length and similar size of the capping group (SPCL15-HPG90, SPCL35-HPG90 and SPCL60-
HPG90) in order to study the effect of the chain length upon encapsulating large molecule. 
Hydrophilic HPG was synthesised as the only control system of our proposed drug delivery 
system. The aggregation was then studied using pyrene as probe. The study showed that both 
the star copolymer (SPCL60-HPG90) and the control (TMP1-HPG90) aggregate and form 
micelles at 10-20 µg/mL and 150 µg/mL, respectively. Having synthesised successfully the 
proposed drug delivery system and the control, a model macromolecular guest, a synthetic 
mimic of hemoglobin, was selected for the encapsulation. It is proposed that encapsulation of 
the synthetic mimic of hemoglobin (TAPP-HBP 15) within the core of the star copolymers 
improved its water solubility and making it artificial blood product. The guest was synthesised 
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successfully with an average molecular weight of 18K Da. Upon encapsulation, significant 
amount of the guest was loaded within the star copolymers than the control system by 10 
factors. The encapsulation of the guest is thought to happen with the aggregated structure of 
the polymer rather than within the structure of the host. This was concluded because although 
the HPG does not have hydrophobic segment, it has encapsulated the large guest. 
 The second part of the project discussed the synthesis of star copolymers with porphyrin core 
for photodynamic therapy (PDT). PDT is one of the outstanding protocols for cancer treatment, 
which involves the combined action of photosensitizer (PS), once accumulated into cancer 
cells, and irradiation with the light of appropriate wavelength. Porphyrins and their derivatives 
have been used extensively in PDT. Although PDT is an alternative therapeutic method to 
traditional cancer treatment, there are still a number of problems, which limit its clinical 
application. These include selectivity, solubility and therapeutic efficiency.  In this study, the 
solubility of porphyrins in aqueous solution was enhanced significantly via covalent 
incorporation within aggregated water-soluble polymers (porphyrin cored star copolymers). 
Two porphyrin molecules with hydroxyl end group were selected as a core for the star 
copolymer, these are: tetrakis(3,5-dihydroxyphenyl) porphyrin) (TDHPP), and tetrakis(4-
(hydroxyphenyl)porphyrin (THPP). However, TDHPP and THPP were very unreactive 
initiators and did not polymerise with the caprolactone until a spacer was added to the 
porphyrin so that the lone pair of their terminal hydroxyl group cannot be part of the porphyrin 
conjugation system. Thus, two star copolymers were synthesised from spacer-porphyrin (S-
THPP-PCL-HPG) and S-TDHPP-PCL-HBP). The control (porphyrin-HPG) were synthesised 
from porphyrins with and without spacer units. The particle size of all the aggregated polymers 
was between 100-200 nm determined by DLS. As such, favourable/selective delivery via the 
enhanced permittivity and retention effect (the EPR effect) was expected. The polymers were 
analysed for their PDT behaviour via a simple MTT assay, using EJ bladder carcinoma cell 
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line. The relative viability of the polymers and its controls in the dark were higher than 0.8 at 
100 µM except the THPP-HPG polymer which had aviability of 0.2.  
Under light irradiation (10 mW/cm2), significant toxicity was observed at 1 µM for the free 
THPP and at 10 µM for the free TDHPP porphyrin. While phototoxicity of the polymers, 
considerable cell death was obvious at polymers concentration of 10 µM for the THPP cored 
polymers except the star copolymer, which did not show any significant toxicity at this 
concentration. The phototoxicity of TDHPP cored polymers were significant for TDHPP-HPG 
and S-TDHPP-HPG at 100 µM for and poor for the star copolymer at the same concentration. 
The intracellular localisation of the molecules porphyrin cored polymers into the EJ cells was 
imaged by confocal microscopy. Both of the free porphyrin (THPP and TDHPP) molecules 
diffused within the cell at 10 µM.  Porphyrin cored HPG polymers also diffused within the 
cells but as the spacer was added the diffused the fluorescence decreased. The porphyrin-PCL-
HPGs star copolymers showed no diffusion into the cells. Thus, porphyrin-cored HPG 
polymers was deemed to be promising photosensitizers for photodynamic therapy (PDT) rather 



























1. Introduction  
The graded development of drug delivery system started with the use of polymeric carriers to 
enhance drug stability and modify the release characteristics. Polymers range from their use as 
binders and film coating agents in tablets to viscosity and flow controlling agents in liquids, 
suspensions and emulsions; to disguise the unpleasant taste of a drug, enhance drug stability 
and of modify the release characteristics. Today, modern drug delivery systems have benefited 
many patients by enabling them receive safer and more effective doses of medicines that are 
desired to fight a variety of human diseases. However, still there are many fatal diseases that 
are not yet cured and threatening human life due to the problem encountered by formulation 
scientists in drug delivery approaches. For this reason, new formulations are being developed 
to achieve a complete therapeutic effect of the existing drug molecules; among these, polymeric 
materials in novel drug delivery approaches are of highly interest.  
1.1. Novel Drug Delivery System 
A Drug Delivery System (DDS) is defined as a formulation or a device that enables the 
administration of a therapeutic substance to desired body location and provides timely release 
of therapeutic agent. The way a drug is delivered can affect its efficacy. Though, the very slow 
progress in the effectiveness of curing difficult diseases, demand a growing need for a 
multidisciplinary approach to the delivery of therapeutics to their targets. From this, new 
development on controlling the pharmacokinetics (PK) and pharmacodynamics (PD) is being 
studied. PK studies investigate the system in which drugs move through the body. It rules the 
route of administration and can be broken down into four different areas (ADME): adsorption 
of the drug, distribution of the drug molecules, metabolism of the parent drug and 
excretion/elimination of the drug and its metabolites. It is vital to keep a balance between these 
processes which ensures the drug stays in the body long enough to show its therapeutic effect 
but not so long that it is regarded as being toxic. PD studies the relationship between the drug 
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concentration at the site of action and the resulting effect of it on the body. This is controlled 
by the way the drug interacts with its target site including the mechanism of action, 
pharmacological response, and affinity to the site of action. Previous studies have shown that 
the drug is most effective when its stereoelectronic structure is complementary with the 
stereoelectronic structure of the target site. [1] 
The drug that possesses the pharmacological activity is called the Active pharmaceutical 
ingredients (APIs). Being small in quantity, the API is usually unable to be administered on its 
own. Therefore, some aiding substances called excipients are added in the API and a dosage 
form is formed that makes it easier to be administered to a patient. Emulsifiers, dyes, lubricants, 
diluents, supporters, and chemical stabilizers are some of the commonly used excipients. Once 
considered inert, the excipients are now known to be selected carefully as they can affect the 
speed and extent of drug absorption and, hence, the drug bioavailability. Immense research is 
being conducted in the field of an effective drug delivery system development. Such a delivery 
system is desired to be made that not only provides a controlled drug release and absorption, 
with special consideration to the poorly water soluble drugs, but also offers a dosage form that 
is convenient for the patient and allows easier administration of drug. 
The high molecular weight carriers for example micelles, hyperbranched polymers and 
dendrimers, are known to form the basic components of the drug delivery systems. The API 
reaches its site of action by the help of these carriers where the API is either attached to the 
carrier’s surface in the form of a prodrug or present within the polymer’s inner core. The carrier 
polymers not only protect the APIs from the harmful effects of the outer environment, which 
renders it pharmacologically ineffective but also prevents the unnecessary interactions of the 
APIs with the macromolecules such as proteins that are responsible to hinder the drug to reach 
its target site of action. An ideal polymeric carrier must have a structure that allows it to release 
the drug at a desired rate and should have the properties like biodegradability. The polymeric 
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carriers adopt certain pathways to be eliminated from the body. Renal clearance (involving the 
kidneys) and metabolic clearance are the two pathways by which the polymers leave the body. 
Usually, the substances with a low molecular weight (approximately less than 50 KDa, which 
may be subject to change based on chemical structure) [2-3] can easily pass the renal glomerular 
membrane and, hence, any polymer with a molecular weight lower than this value can 
effectively be excreted out from the body. It is important to note that the molecular weight is 
the most important factor to be considered in case of substances that are not biodegradable. 
The chemical structure of the polymer, which includes the degree of hydrophobicity, covalent 
bonds between monomers, etc., is the most important factor in ideal polymer design that must 
be considered in case of biodegradable polymers. The reason behind this selection is the effect 
of chemical structure on the other important features like speed and degradation of the polymer 
and, hence, at the rate and site of drug release. Different linkers are used in cases where polymer 
is not biodegradable to release the drug moiety. For example, L. Erdmann et al reported that 
hydrolytic degradation of poly(anhydride ester) yield two equivalents of salicylic acid (SA) 
and one equivalent of sebacic acid. Local release of SA found to promote healing. Drug is 
covalently attached to the polymer via linkers.[4a] These linkers break in response to specific 
conditions such as presence of an acidic medium or different enzymes and, thus, release of the 
drug. Similarly, different target molecules can be used that are attached to the surface of the 
polymer to achieve a directed drug delivery. Also, the use of smart polymers in making of 
carriers is gaining importance. These smart polymers are known to carry numerous benefits, 
which can be modulated by providing certain stimulations. The stimulations are known to alter 
the structure of the polymer, hence, allowing the release of drug at a controlled time and place. 
Some of the major benefits associated with the use of this smart polymer include improved 
pharmaceutical profile and drug stability, maximum biocompatibility with minimum side 
effects and facilitated accumulation of the drug for an extended period at a specific target site. 
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A rational model for pharmacologically active polymers was first proposed by Ringsdorf in 
1975. [4b] The Ringsdorf model mainly involves of a biocompatible polymer backbone 
conjugated to three components: a solubilizer, to ensure water solubility, a drug, bound to the 
polymeric backbone via a linker, and a targeting moiety to provide transport to a desired 
physiological location or bind to a specific biological target. 
1.1.1 Controlled Drug Release Method  
Controlled-release systems aim to improve drug therapy. [5-6] The basic rationale of controlled 
drug delivery system is to optimize the pharmacokinetic and the pharmacodynamics properties 
of drug in such a way that its utility is maximized through reduction in the side effects and cure 
or control of condition in the shortest possible time by the most suitable route.  
Controlled Drug Delivery (CDD) occurs when a polymer is judiciously combined with a drug 
or other active agent in such a way that the active agent is released from the bulk material in a 
pre-designed manner. The purpose behind controlling the drug delivery is to achieve more 
effective therapies while eliminating the potential for both under and overdosing. An example 
of Controlled drug delivery was shown in figure 1.1.  
 
Figure 1.1: Example for Controlled Drug Delivery.[7] 
Different types of drug classes like anti-inflammatory agents, [8-10] antibiotics, [11] 
chemotherapeutic drugs, [12] immunesuppressants, [13] anaesthetics, [14] and vaccines [15] can be 
formulated in the form of controlled release drug delivery systems in order to get the 
distribution or time-controlled drug delivery. This type of drug delivery is essentially beneficial 
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when either the drug reacts with the non-target tissues in its normal distribution path causing 
potential side effects or when the degradation makes it unable for the drug to reach its specific 
site of action.  
1.1.2 Time-Controlled: Modified-Release Formulation 
As the name indicates, in these formulations, the release of the drug is controlled. The drug is 
released at a controlled rate and ultimately achieves the desired therapeutic concentration at the 
target site. Figure 1.2 shows the case of a singly administered dose of a drug showing the 
achievement of an immediate (short-term) therapeutic concentration of the active ingredient. 
[18]  
 
Figure 1.2: Curve of drug concentration in plasma over time after a single dose [16] 
 
It can be seen from figure 1.2 that the drug continues to be absorbed until it reaches its 
maximum concentration (or till the desired bioavailable dose gets absorbed) followed by a slow 
and steady fall in drug absorption which is shown by the gradual decreses drug concentration 
in the plasma. [19] This gradual drop actually shows the elimination phase of the drug, which is 
dependent on both the metabolism and excretion. The minimum concentration of drug that is 
required to get desired pharmacological effects is called the effective (therapeutic) 
concentration whereas the concentration above which there are chances of occurrence of side 
effects or toxic effects is called the maximum safe concentration. Between the effective 
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(therapeutic) concentration and the maximum safe concentration lies the area which is termed 
as the therapeutic window and the drug concentration must lie in this therapeutic window to 
give the desired therapeutic effects. Figure 1.3 shows a chronic treatment case where multiple 
doses are administered at regular intervals. It is in this case where there are higher chances of 
under or over dosing due to alterations in the API concentrations. The drug concentrations 
higher than the desired therapeutic concentrations cause toxic effects whereas lower than the 
desired concentrations lead to therapeutic failure. 
 
 
Figure 1.3: Drug concentrations in plasma after delivery by conventional injection in a chronic disease[17] 
Strict adherence to the drug administration pattern is required in case of chronic treatments to 
prevent the events of drug toxicity. Half-life is an important factor that must be considered in 
case of these multiple dosing treatments. Half-life is actually the time that is taken by a drug to 
reduce its concentration by one half after reaching the systemic circulation. Multiple drug doses 
are generally administered at the intervals of two times the half-life of the drug in systemic 
circulation. The modified-release formulation, on the contrary, is believed to deliver the drug 
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at a speed or at a site (other than the administration site) that is determined before the actual 
administration of the drug. 
1.1.3 Controlled Distribution 
Drug carriers with a controlled distribution system are used in case of controlled drug 
distribution, which allows the distribution of drug at the desired target site. Different methods 
are being employed in order to achieve controlled drug distribution. 
Use of molecular tracking devices is one of the most commonly used methods to get targeted 
drug distribution. Research in molecular biology has established that certain receptors are over 
expressed in diseased tissues as in case of cancer. If these receptors on the targeted diseased 
tissues are recognised, then the surface of the nano- and micro-drug-polymers complex can be 
modified by attaching receptor recognition elements or tracking devices; hence, a controlled 
drug distribution at a specific target site can be achieved (see figure 1.4). Antibodies [20-21], 
carbohydrates [22] and simple electrically charged species are some of the commonly used 
tracking devices [23].  
 
Figure 1.4: Polymer functionalized to interact with specific targets [24-26] 
Another approach to achieve a controlled distribution is by the use of hydrogels. In this 
approach, the drug is either encapsulated or absorbed in a hydrogel, which is then released by 
28 
 
diffusion through the hydrogel system. An interesting feature of this approach is that the release 
of drug from the hydrogel is triggered by different external stimulus, which are studied and 
explained extensively by Qiu et al. and Gupta et al. [27-28]  
Following different controlled drug release models/systems are studied: the pH-dependent 
system where ionisable groups are present in the hydrogel structure, which responds to changes 
in pH by showing attraction and repulsion among the molecules of its structure, hence, stopping 
and allowing the drug release respectively,  electrical signals-controlled drug release systems 
where electrical signals cause changes in the pore size and permeability and hence the release 
of drug were studied as well as the temperature-dependent hydrogel systems. In addition to 
that, specific substances-dependent drug release systems where the concentration of substances 
in the external environment (like glucose, urea and morphine) alters the drug release and 
systems bearing specific linker molecules [29] that are degraded in the presence of acidic 
environment (for example the endosomal acidic environment and tumor tissues) or specific 
enzyme (for example the lysosomal environment containing proteolytic and hydrolytic 
enzymes) cause drug release were also studied. 
Endocytosis [30] is the process by which molecules enter into cells. Firstly, the cell membrane 
folds’ inwards results in the formation of a small vesicle called endosome. This endosome then 
merges with a lysosome and forms secondary lysosome, which contains an acidic internal 




Figure 1.5: Endocytosis is the process by which molecules enter into cells. [30] Firstly, the cell membrane 
folds’ inwards results in the formation of a small vesicle called endosome. This endosome then merges 
with a lysosome and forms a secondary lysosome, which contains an acidic internal environment with 
enzymes where the linker molecules break and release the drug. [31] 
It is the specific environment of the endosome, lysosome or the tumor tissue where the linkers 
are cleaved in order to release the drug, not under normal circumstances [32], like the labile acid 
linkers such as cis-aconityl or hydrazone which specifically degrade in the acidic tumour tissue 
or endonomal environment. [33] Similarly, protein-containing linkers can be destroyed when in 
the lysosome as lysosome bears the enzyme responsible for the cleavage of the peptide bond. 
The breakage of the linker molecule is followed by the drug release that is then diffused into 
the cytosol of the cell, figure 1.5. Peptides and oligosaccharides are the linker molecules used 
most commonly in controlled drug release systems. Some of the important linkers included in 
the linker library by VectraMed include lysosomalendoproteases, Cathepsin B from the 
Cathepsin family, which mainly target the cancer tissues. [34] Prostate Specific Antigen targets 
the prostate tumours and the Proline peptidases, which are highly abundant in case of 
pulmonary hypertension and during inflammation. 
1.1.4 The enhanced permeability and retention (EPR) effect 
 Nano-delivery systems must have certain criteria when used in the desired application. The 
delivery system should have a certain particle size, hydrophobicity and surface charge to 
overcome physiological barriers (biological structures or physiological mechanisms) that 
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prevent nanoparticles from reaching their targets. The biological barriers are prevented when 
the nanoparticles show effective extravasation over the vasculature, improved cellular uptake, 
prolonged vascular circulation time and endosomal or lysosomal escape. 
In the recent past, polymeric carriers of antineoplastic drug molecules have been widely 
studied. [35] These polymeric carriers accumulate (passively) around tumours tissue due to 
differences in the biochemical and physiological characteristics of normal and cancerous tissue. 
The passive accumulation of therapeutic in tumour tissue is known as the enhanced 
permeability and retention (EPR) effect, which was first reported by Maeda et al. [36] (Figure 
1.6). Usually small molecules diffuse through the endothelial cell wall to normal and cancerous 
tissues. Nevertheless, macromolecules can reach only malignant tissues because the walls of 
the endothelial cells of these tissues are fenestrated, resulting in pores that allow 
macromolecules to cross. Malignant tissue has other features include increased vascularity 
(angiogenic process) and poor lymphatic drainage and, which both lead to the retention of 
macromolecules. Therefore, therapeutic compounds can be delivered to the site of action in a 
safe and efficient manner by either an active or a passive process. The former includes the use 
of peripherally conjugated targeting moieties for enhanced delivery to the site of action. The 
passive process refers to transport through leaky capillary fenestrations into malignant tissues 




Figure 1.6: Schematic representation showing the  anatomical and physiological characteristics of healthy 
and malignant tissue in term of the vascular permeability and retention of small and large molecules (EPR 
effect). [27] 
When macromolecules reach the tumur tissue, they are either endocytosed (receptor-mediated 
endocytosis) or phagocytosed (internalization without the mediation of receptor) by the tumur 
tissues forming endosome (vesicle). Since the pH in these endosome vesicles (6.5- 5.0) is lower 
than that of the extracellular matrix (7.2-7.4), acid-labile linkers are hydrolysed and hence 
releasing the encapsulated drug molecule. In the final step a secondary lysosome is formed as 
a result of the endosome being absorbed by a lysosome. The secondary lysosome includes 
hydrolytic and digestive enzymes, which are active in acidic environments.  
1.1.5 Drug encapsulation 
There are two different type of encapsulating a drugs within polymeric carriers; these are non-
covalent and covalent encapsulation (Figure 1.7). In the former case the drug is physically 
entrapped within the structure of a polymer. This approach may retain the chemical integrity 
and pharmacological properties of the drug molecule; however, it provides little in vivo 
evidence of therapeutic benefit as there is no control over the release of the drug molecule.  The 
alternative approach is to covalently link the drug molecule to the surface of the polymer as 
part of a pendant group in what is called a polymer-drug conjugate. The idea of conjugating a 
drug to a water-soluble polymer was first proposed by Ringsdorf in 1970.[4b] Drugs can be 
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connected to the backbone either directly or via linkers or spacers. The biodegradable linkage 
provides an alternative to solubilisation and electrostatic association. The drug can be release 
via chemical or enzymatic cleavage of hydrolytically labile bonds.   
 
Figure 1.7:Examples of covalent and non-covalent encapsulation [37] 
1.1.6 Polymeric system: synthesis and application 
1.1.6.1 Amphiphilic copolymers  
In aqueous media molecules containing a hydrophobic and hydrophilic segment (amphiphilic) 
form aggregates called micelles or self-organisation . In amphipathic polymers, hydrophilic 
part forms the outer shell in contact with water, while the hydrophilic part is sequestered in the 
interior. Micelles form only when the concentration of the amphiphilic copolymer is greater 
than the critical micelle concentration (CMC) [38]. The formation of micelles is monitored by 
the rapid change in the chemical and physical properties. Below the CMC, micelles are totally 
absent, Figure 1.8. The use of amphiphilic copolymers as drug carriers involves the 
incorporation of low molecular weight drugs in the interior region for improving therapeutic 
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efficacy. Accordingly, the core of polymeric micelles (hydrophobic domain) help the 
encapsulation of hydrophobic drug molecules either via covalent or non-covalent interactions.  
 
 
Figure 1.8: Free Surfactant Molecules below CMC (left) and above CMC forming a micelle (right) 
There are number of advantages for using micellar systems as drug carriers. One of which is 
their capability of encapsulating hydrophobic drugs, thereby permitting circulation through the 
blood due to the solubility and stability of the complex in physiological environment. In 
addition, the drug molecule will be safe from embolization by enzymes or another bioactive 
species. Moreover, micelles have long half-life in the body for being large and hence they 
cannot be filtered from kidney. Therefore, the drug molecule activity remains in the blood 
circulatory system for a long time after injection. The renal route because of their composition 
and structure slowly excretes these polymeric structures.  
The outer layer in polymeric micelles responsible for interactions with biostructures (such as 
cells and proteins), and these interaction controls the pharmacokinetics and biodistribution of 
the drug molecule. Example of the outer layer is polar poly(ethylene oxide) (PEO) that forms 
the shell of the micelle and protects its interior. Polymer micelles have been widely studied for 
improving the solubility and selectivity of poorly soluble and toxic chemotherapeutic drugs 
though passive mechanism (EPR effect) or active mechanism for enhanced delivery to the site 





1.1.1.1 Dendritic Polymers 
Dendritic macromolecules, which refer to dendrimers and hyperbranched polymers, are highly 
branched molecules with three-dimensional dendritc architecture coined by Tomalia et al. 
Dendritic polymers constructed from multifunctional monomers and that possess a high degree 
of branching which leads to large number of functionalised end groups. These end groups are 
designed to facilitate solubility in a solvent, which can dramatically affect the overall properties 
of the branched system. Accordingly, these polymers have attracted much interest from the 
pharmaceutical industry who is trying to develop and tailor their behaviour. 
Hyperbranched polymers, in comparison to dendrimers, possess high polydispersity. Their 
highly branched architecture and chemical tenability makes them efficient drug carrier systems. 
In 2011, Kolhe et al has researched the potential use of hyperbranched polymers as drug 
delivery agents. [40] The research consists of the encapsulation of both hyperbranched polyol 
and polyglycerol. These two polymers could form conjugates with large numbers of ibuprofen 
molecules when the ester linkages occur between the polymers and the drug. The 
hyperbranched polymers achieved high loading and showed a significant therapeutic effect in  
in vivo studies. Another study for the hyperbranched polyglycerol has been carried to 
encapsulate the hydrophobic anticancer drug, tamoxifen. This study showed that the solubility 
of the drug allows 12 times more to be transported into an aqueous phase in comparison to the 
free drug molecule. [41] These two studies proved that hyperbranched polymers can be used as 
a potential drug delivery agent.  
1.1.1.2 Synthesis of Hyperbranched Polymer  
In 1952, Flory highlighted the synthesis of hyperbranched polymers from ABn monomers 
(where n ≥ 2) for forming highly branched soluble polymers. [40] In contrast to dendrimers, the 
synthesis of hyberbranched polymers is a one-pot process, [40-41] which, results in a significant 
time advantage over the synthesis of dendrimer. Consequently, hyperbranched polymers can 
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be prepared in large quantities. Unlike dendrimers, hyperbranched polymers possess a broad 
molecular weight distribution rather than a monodisperse product. Hyperbranched polymers 
can be prepared using three synthetic approaches: step growth polycondensation of ABn 
monomers and A2 + B3 monomer
[84,85]; self-condensing vinyl polymerization[86-88]; and ring-
opening polymerization[89-91]. 
1.1.1.2.1 Step Growth Polycondensation 
This type of polymerisation of ABn monomers (where n ≥ 2) has been widely used for 
preparing a wide range of polymeric products including polyphenylenes, [41] polyesters, [42a] 
polyethers [42b] and polyamides. [42c] Branching units of hyperbranched polymers are produced 
each time both B functionalities of one molecule react with a function of A groups contained 
on others. There also possibilities that only one B functionality react which results in some 
linear character in the hyperbranched polymer (Figure 1.9). The AB2 type of monomer is 
popularly used due to their ease of preparation at low cost. Other type of monomers that contain 
as many as six B type functionalities (AB6) have been reported in the synthesis of polyester 
and polysiloxanes. Many other possibilities exist such as using A2 and B3 monomers but these 
reactions are difficult to control. The drawback of this method is unwanted side reactions such 
as cross-linking which may cause gelation during the synthesis. Gelation makes the product 
insoluble in organic solvents, which, in turn leads to significant difficulties in purification of 
the desired product. In addition, this approach is less commercially viable due to the importance 




Figure 1.9: Step growth polycondensation 
1.1.1.2.2 Self-condensing Vinyl Polymerisation  
The self-condensing vinyl polymerisation (SCVP) approach was introduced by Fréchet and co-
workers in 1995. [44] SCVP uses use of one vinyl group and one initiating moiety (AB* 
monomers) to produce hyperbranched polymers (Figure 1.10). The activated species can be a 
radical, anion, cation or carbanion. In order to avoid side reactions that may cause gelation, 
living or controlled polymerisation systems are employed.  
 
Figure 1.10:  Self-condensing vinyl polymerization 
 
1.1.1.2.3 Ring-opening Polymerisation  
This approach was first developed by Suzuki for the ring-opening multi-branching 
polymerisation of latent AB(B) monomers. [45] The terminal function of a polymer acts as a 
reactive centre on which further cyclic monomers bond to form a larger polymer chain through 
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ionic propagation. In this synthetic method, each additional monomer step forms another 
reactive centre, shown schematically for ring opening polymerisation of glycidol below in 
Figure1.11. Examples of hyperbranched polymers produced by this method are polyamines, 
polyethers and polyesters. 
 
Figure 1.11: Ring opening polymerization 
 
1.2 Photodynamic therapy  
Photodynamic therapy, often known as photochemotherapy, [50] is a treatment involving a 
photosensitizing agent and a light of specific wavelength used in conjunction with molecular 
oxygen to cause cell death. PDT has proven to be effective in treat many medical conditions, 
including microbial cells (bacteria, fungi and viruses), acne, wet age-related macular 
degeneration, psoriasis and atherosclerosis. [48] It also treats malignant cancers [49] including 
lung, esophageal, bladder, and gastric tumours. In 1990, PDT utilized Photofrin as a 
photosensitizing agent for cancer treatment. The major drawback of the FDA approved PDT 
agents (photosensitizers) is skin sensitization as a side effect of the treatment and poor light 
absorption near the IR region. [51] Therefore, it is vital to develop new PDT agents that can also  
these limitations while achieving the target criteria for effective PDT treatment. The 
mechanism of PDT involves different components; defining and exploring them help in 
understating the mechanism. Basically, a PS agent is administrated, and then activated by light 
of a specific wavelength. The presence of molecular oxygen activates the PS and can create the 
photodynamic reaction, which is tumour and vascular ablative. In this review, each component 
will be considered individually, and how can affect the mechanism of PDT. 
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1.2.1 Photosensitizers agents (PSs) 
Both dyes and pigments reflect absorbed light into certain wavelength that result in the 
precipitation of the colour. The difference between PSs and dyes is that PSs are able to transfer 
the energy of absorbed light electronically to adjacent molecules or used in photochemical 
reactions. [52] PSs are a key component of PDT, which used in the treatment of some cancer 
and other medical conditions. They are divided into porphyrin and non-porphyrin based 
molecules. Sample of porphyrin-based PS molecules include chlorins, bacteriochlorins, 
phthalocyanines, and pupurins. [53,54] example of non-porphyrin based PS molecules include 
anthracyclines, cyanines, hypericin, psoealens and phenothiazinium molecules (Nile blue 
analogs, methylene blue, toluidine blue and acridines).[51] Figure show 3.1 shows examples of 
porphyrin and non-porphyrin based PS.  In PDT, the ideal PS should satisfy the key target 
criteria including high selectivity toward tumours, production of reactive oxygen species or 
free radicals, near the IR light, high molar extinction coefficient, absorption, optimal of ADME 




Figure 1.12: Examples of porphyrin (i-iv) and non-porphyrin based PS systems (v-vii) 
1.2.1.1 Hematoporphyrin derivative (HPD)  
HPD (Photofrin) was the first PS brought to the market, by Dougherty in the 1970’s. HPD is a 
collection of several monomers, dimmers, and polymers of hematoporphyrin that all necessary 
for effective PDT. This PS considered safe and does not cause pain when activated with light 
allowing reliable and easy outpatient treatment. However, the treatment time of the HPD 
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requires 20 minutes or more per lesion. HPD can cause severe skin burns if the patient 
unintentionally exposed to sunlight. 
 
Figure 1.13:Chemical structure of Photofrin, a mixture of hematoporphyrin dimers and oligomers 
1.2.1.2 M-tetrahydroxophenyl chlorine (mTHPC)  
This PS produces fast and significant photodynamic reaction with treatment time measured in 
seconds. However, the treatment is painful and so the activation of the drug done whiles the 
patient under anesthesia. In addition, patients treated with this drug stay in a dark room for 24 
hours to avoid skin burn that can happen by the expose with strong light. Still, the drug has 
found a place in treating primary and recurrent head and neck cancers because of it is high 
effectiveness. 
1.2.1.3 Mono-L-aspartyl chlorine e6 (NPe6)  
Chlorine e6 is a very effective PDT agent, does not have the dark toxicity common with 
mTHPC, and treatment allowed for few hours after infusion. Unlike the photofrin and mTHPC, 





Figure 1.14: Chemical structure of chlorine e6 
1.2.2 Therapeutic irradiation  
Each PS has a specific wavelength of light and for effective activation; the intensity of light 
should be higher than 630 nm.[55] Clinically, excitation at wavelength in the IR region can leads 
to deeper penetration.  The therapeutic irradiation window, preferred range of wavelength, has 
been reported to be 630-800 nm by some [56] and 650-950nm by other [57]. PS with high molar 
absorptivity (>20,000) can reduce the required dose of the PS for PDT treatment. [58] 
1.2.3 Photophysics 
The process of light absorption and energy transfer are the two most significant aspects of PDT, 
see illustration in figure 3.2. The ground state of PS (two electrons with opposite spins) in the 
low energy molecular orbital known as singlet state PS. Upon absorption of light in the form 
of photons, one of these electrons is boosted into a high energy orbital keeping its spin from 
the first excited singlet state 1P*. This species has very short lifetime (in nanoseconds) and can 
lose its energy by emitting light or by internal conversion. Intersystem crossing process occur 
when the spin of the excited singlet state 1PS* inverts to produce long-lived excited triplet state 
(3P*) (microseconds) that has electron spins in parallel conformation. The loss of energy of the 
3P* by emission of light (phosphorescence) is known as pin-forbidden” process where the PS 




In PDT, PS efficiently populates an excited triplet state when irradiated with light near the IR 
region. This triplet state (3PS*) can produce toxic reactive oxygen species (ROS) such as free 
radicals or 1O2 in two different pathways (Fig. 2). In type 1, the 
3PS* reacts directly with cell 
membrane or molecule to produce a radical anion or radical cation, respectively. In turn, these 
radicals further react with oxygen to generate reactive oxygen species. Otherwise in Type 2 
reactions, the 3PS* can transfer its energy directly to molecular oxygen in its ground state to 
produce excited state singlet oxygen. Both Type 1 and Type 2 reactions can occur 
simultaneously, and the ratio between these processes depends on the type of PS used, the 
concentrations of substrate and oxygen.  
 
 
Figure 1.15: Formation of PDT ROS through type 1 and 2 [62] 
Both Type 1 and Type 2 reactions can occur simultaneously, and the ratio between these 
processes depends on the type of PS used, as well as the concentrations of substrate and oxygen. 
Due to the high reactivity and short half-life of singlet oxygen and hydroxyl radicals, only 
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molecules and structures that are proximal to the area of its production (i.e. areas of PS 
localization) are directly affected by PDT and are subsequently destroyed. [62] 
1.2.5 Mechanisms of cell death in PDT 
Photodynamic therapy can lead to cell death via pathways including apoptosis and necrosis. 
Necrosis is an unprogrammed cell death pathway that can be induced by injury, infection, heat, 
cancer, infarction, toxins, and inflammation.[63] It is quick method of degradation that can be 
characterized by damage to organelles, cytoplasm swelling, and disruption of the cell 
membrane. Necrosis takes place when high doses of light are being used. Unlike necrosis, 
apoptosis can be characterised morphologically as single cells which surrounded by other 
normal-looking cells and is distinguished by cell shrinkage. In vitro, apoptotic cells degraded 
into multiple membrane enclosed spherical vesicles. However, in vivo, these vesicles can be 
scavenged by phagocytes whereas inflammation can be prevented [63]. Recent studies have 
shown that autophagy plays a role in PDT [64]. Autophagy is a vital transportation process 
through lysosomal degradation pathways that associated with cell survival, development, and 
differentiation. Toxic oxidized protein can be developed when proteins undergo irreversible 
ROS damage, autophagy will be activated to remove these toxic species. In the case of failure 
to stimulate these mechanisms, accumulation of oxidized macromolecules will take place and 
the functions of the cells will be compromised which ultimately leads to cell death [65]. The 
effectiveness of PDT depends on the location at which light has been delivered. PDT can also 
lead to tumour death by deprivation of oxygen and nutrition PSs differ in terms of 
biodistribution and pharmacokinetics. After their injection into the blood stream, they can bind 
to endothelial cells, then bind to the extracellular matrix or then accumulate within the tumour 




1.2.6 Use of Nanoparticles 
The selectivity of PS was increased by using a molecule having high affinity to cancer cells, 
such as folic acid [67-68] or antibodies [69], peptides, LDLs, and polymers [70]. Third-generation 
PSs is one approach designed to target subcellular compartments such as mitochondria [71]. The 
second approach includes utilising nanoparticle-based drug delivery methods in PDT. The 
usage of nanoparticles in PDT studies has very attractive following reasons: (1) monomeric 
form of PSs can be used within nanoparticles; (2) lower levels of the PSs can be used for PDT; 
(3) hydrophobic PTD agents have been approved by the FDA and nanoparticles can boost the 
selectivity of these compounds to reduce side effects after treatment as well as aggregation 
problems; (4) applying strategies such as pH sensitivity, thermal sensitivity, peptide or 
antibody tags in nanoparticle system can boost selectivity more efficiently; (5) passive 
targeting through EPR system by making nanoparticles with a diameter of less than 200 nm; 
(7) increase in cell uptake [72-73]. Examples of some of the nanoparticles that have been used in 
PDT studies so far include micelles, polymeric micelles, carbon nanodots [74], liposomes [75] 
quantum dots, gold nanoparticles [76-77], catanionic vesicles [78], hydrogels [79], and dendrimer 
nano particles [80-81], TiO2[82]. 
In summary, polymeric material have been used widely as drug carrier to improve the 
effectiveness and reduce the toxicity of drug molecules. In this research, new drug delivery 
















2. Aims and Objectives 
2.1 Synthesis of star copolymers for large drug delivery system 
Advances in biology, molecular genetics and human genomics are starting to generate new 
pharmacologically active biomolecules. However, these emerging biomolecules are much 
larger than traditional drug molecules and undergo rapid degradation in a biological 
environment, often resulting in severe toxicity. Therefore, the application of these 
pharmacologically active biomolecules as therapeutic drugs will require the use of new 
delivery systems.  
The aim of this project is to generate a general delivery system that can be used to deliver large 
drug molecules; including biomolecules (peptides, proteins, RNA etc.). This delivery system 
will consist of a large star shaped polymer that possesses many long arms, each terminated 
with a large globular polymeric unit. These terminal units are designed to interlock and help 
prevent the internal arms from collapsing (steric stabilisation).  Thus, the internal arms are 
prevented from collapsing/coiling, leaving large amounts of internal space. Large drug 
molecules can occupy this “free” space.  In addition, the polymers are designed to degrade 
slowly in a neutral solution but rapidly in acidic solution.  This controlled degradation can be 
exploited to trigger drug release under certain conditions.  
2.1.1 General Design of the Proposed Drug Delivery System (Star Copolymers) 
and control systems 
This project will start by constructing nano-sized macromolecular carriers with the capacity to 
form and maintain a large volume of free internal space. The general design is shown 
schematically in scheme 2.1 b. A star polymeric core will be used to generate a suitable 
environment that can be used to encapsulate large drug molecules. Without any further 
functionalization, there is nothing to stop the arms from simply collapsing or coiling in aqueous 
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solution (significantly reducing the level of free space), scheme 2.1 a.  To prevent this, 
hydrophilic highly branched polymer (HBP) will be added to the ends and used as steric 
capping groups to lock the structure in an open conformation and therefore maximising the 
internal space, scheme 2.1, b.  
 
Scheme 2.1: A cartoon representation of the proposed drug delivery system  
To optimise the desired amount of internal space and capping density, allowing specific drug 
molecules to efficiently enter and leave the delivery system, the size of the terminal capping 
groups and the length of the internal arms is optimised. This will be achieved experimentally 
by varying the size of the terminal groups and the length of internal polymer arms.  Care must 
be taken to obtain a balanced system.  For example, small capping groups may not provide 
enough water solubility to the hydrophobic star polymer, whereas large capping groups can 
maximise delivery times (by trapping drugs within the interior spaces), but they can also make 
it very difficult to get significant amounts of drug into the delivery system. 
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2.1.2 Control system 
Since the proposed delivery system consist of two segments (hydrophobic chains and 
hydrophilic capping groups), the two parts should be investigated independently as control 
systems. However, the hydrophobic star polymer or single chain does not have any water 
solubility, as illustrated in the main aim, scheme 2.1 a, hence, only the hydrophilic HPG will 
be studied as a control system of the proposed drug delivery system. 
2.1.3 Testing the macro-encapsulation potential of the star copolymers  
Having establish the parameters and properties for possible aggregations, encapsulation of a 
model macromolecular drug using a hydrophobic macromolecule will be investigated. A 
synthetic mimic of haemoglobin which is water insoluble will be chosen to improve its 
solubility in water. Specially, encapsulation of  porphyrin cored hyperbranched polymer (HBP 
15, figure 3.3) within the star copolymers and the control system will be tested. 
 
Scheme 2.2 : A cartoon representation of the aqueous solubilisation of  hydrophobic HBP upon 





Figure 2.1: The chemical structure of the porphyrin cored hyperbranched polymer (HBP 15) as a macro-
guest  
2.2 Porphyrin-cored star copolymers for photodynamic application 
In a previous study carried out by the Twyman group, different porphyrin molecules were 
successfully encapsulated within dendritic molecule. These systems showed good 
encapsulation results that could potentially be investigated for PDT. However, the encapsulated 
porphyrin molecules may be released from the delivery system at any time before reaching the 
target, reducing their selectivity. As such, it was disarable to develop a delivery system where 
the PS was covalently attached within a macromolecular delivery system. 
In this study, star copolymers comprising a porphyrin at the central core and a number of 
hydrophobic arms, each terminated with hydrophilic units, were synthesised. Specifically, each 
copolymer arm comprises an inner hydrophobic poly(e-caprolactone) arm attached to a 
porphyrin core. The outer layer is a hydrophilic hyperbranched polyglycerol unit, covalently 
attached to the poly(e-caprolactone) arms. In aqueous solution, the proposed amphiphilic star 
copolymers should aggregate to form micelles with diametes 10–200 nm. These large self-




Figure 2.2: Possible self-assembly of porphyrin-cored star copolymers 
As a control, a simpler porphyrin hydrophilic hyperbranched polyglycerol will be used, as well 
as experiments using just the porphyrin core. The main aim is to solubilise and protect a 
porphyrin PS within an amphiphilic molecule that could self-assemble into a large structure 
that could clarify the mechanism of the EPR effect by these molecules. Tetrakis(4-
hydroxyphenyl)-porphyrin (THPP 12) and tetrakis(3.5-dihydroxyphenyl)-porphyrin (TDHPP 
13), were selected as the porphyrin core for use within the delivery system, figure 2.3. These 
possess nucleophilic hydroxy groups that enable a ring opening polymerisation (ROP) to take 
place at the caprolactone and/or glycidol. 
Upon successful synthesis of the proposed delivery system, the dark toxicity, phototoxicity and 
porphyrin uptake will be evaluated using appropriate cell lines. The phototoxicity of the 




Figure 2.3: Potential porphyrin derivative to be used as a core in drug delivery systems for PDT 
applications THPP 12 and TDHPP 13 
 
2.3 Chemo-Photodynamic Combination Therapy  
Cancer is an inclusive term, first assigned by the ancient Romans, for a large group of diseases 
involving abnormal cell growth with the potential to spread to adjacent tissues, resulting in 
uncontrolled cell proliferation and loss of cellular differentiation. There are over 10 million 
new cases of cancer every year and over 6 million annual deaths from cancer. Nowadays, 
cancer is mostly treated by therapy involving the modulation of a single target. A tumour-
targeting drug delivery system consists of a tumour detection moiety and cytotoxic molecule 
(chemotherapeutic molecule) combined directly, via encapsulation or through conjugation. 
Photodynamic therapy (PDT) is a treatment that involves the combined action of 
photosensitisers and light of specific wavelength to treat various cancers. The combination of 
these two therapies, chemotherapy and PDT, make cancer treatment more effective.  
The present project investigates the use of combined anticancer therapies where both 
photosensitiser and chemotherapeutic molecules are included in one drug delivery system; one 
molecule being covalently attached to the corona (photosensitiser) and the other being non-
covalently attached to the system (chemotherapeutic molecule). 
52 
 
In the previous chapter, porphyrin molecules and photosensitisers were attached covalently to 
a hydrophilic hyperbranched polymer or to star copolymers for their use in photodynamic 
therapy (PDT). In this chapter, the potential of the self-assembled porphyrin-delivery systems 
to encapsulate lipophilic chemotherapeutic drug molecules (such as a paclitaxel) into the core 
region of the micelle is investigated. Such drug delivery systems which combine PDT and 
chemotherapy strategy can offer fast and effective treatment for cancer, especially for those in 




3. Synthesis of star copolymers for large drug delivery systems 
3.1 Synthetic considerations  
Construction of the drug delivery system proposed in the previous chapter began with a multi-
step reaction using a single-pot procedure. A core functionalized with hydroxyl end groups was 
proposed as an initiator to ring open and polymerize ε-caprolactone. The resulting hydrophobic 
star polymers were predicted to possess a nucleophilic end group that could then be used to 
initiate a second ring opening polymerization (ROP) using a branched hydrophilic monomer 
(Scheme 3.1).  
 
Scheme 3.1: Reaction design of the proposed drug delivery system, where R2 represents the hydrophobic 
arms resulting from the polymerisation of the caprolactone monomer with nucleophilic hydroxyl end 
groups of the core (R1). R3 is the hydrophilic branched polymer resulting from another ROP of another 
monomer. 
The three components (core, monomer 1, and monomer 2) chosen for our proposed delivery 
system are shown in Figure 3.1. The branched unit trimethylolpropane (TMP) 1 was 





Figure 3.1: Chemical structure of the trimethylolpropane 1,epsilon-caprolactone 2 and glycidol 3 selected 
for the proposed copolymers. 
The hydrophobic component selected for the arms was ε-caprolactone (ε-CL) 2, which would 
result in PCL arms. Poly(caprolactone) (PCL) has the advantages of being approved for human 
use and being biodegradable and compatible with a wide range of other polymers.[45] The 
terminal hydrophilic hyperbranched polymer group would be formed by reacting the hydroxyl 
end group of PCL with glycidol 3 to obtain a hydrophilic polymer.  
3.2 One-pot synthesis of the poly (ε-caprolactone)-b-polyglycerols (PCL-HPG) 
Amphiphilic SPCL-HPG 5 star copolymers were synthesized in two steps using a one-pot 
synthesis (Scheme 3.2). In the first step, poly (ε-caprolactone) (PCL) 4 was synthesised using 
0.05% w/w tin(II)-ethyl hexanoate to catalyse the  ring-opening polymerization (ROP) of ε-CL 
2 formed by the hydroxyl-functionalised core 1 in the bulk at 130 °C.  The target molecular 
weight for PCL depended on the molar ratio of ε-CL 2 to the core hydroxyl groups. The next 
step was subsequently started by reducing the temperature and adding 1,4-dioxane. Potassium 
methoxide was used to deprotonate the hydroxyl groups of PCL 4, followed by the slow 
addition of glycidol 3. The molar ratio of glycidol to the terminal hydroxyl groups of the PCL 
was also varied to adjust the size of the HPG ends. In this work, three star copolymers were 
prepared with different chain lengths and similar size of the capping group to study the effect 




Scheme 3.2: Reaction scheme of synthesising amphiphilic copolymer 5 based on poly (ε-caprolactone) and 
polyglycerols (SPCL-HPG) 
3.3 Anionic ring opening polymerization of forming poly (e-caprolactone) 
The reaction mechanism for the ring opening of ε-CL 2 is shown in Scheme 3.3. To increase 
its electrophilicity, the tin atom of Sn(oct)2 initially coordinates with the ε-CL 2 carbonyl 
oxygen atom through its non-binding electron pair. This results in an increased susceptibility 
to nucleophilic attack by the hydroxyl group. This is then followed by proton transfer and acyl 
oxygen cleavage, resulting in the formation of a PCL molecule with an alcohol-derived ester-
end group and a caprolactone-derived hydroxyl. The process then begins again at i where a tin 
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atom coordinates with a second monomer molecule. The stannous octoate molecule continually 
transfers from one growing polymer chain to another; however, unlike the hydroxyl group 
concentration, the concentration of the stannous octoate does not affect the molecular weight 
of the polymer.   
 
Scheme 3.3: Proposed steps mechanism for the ring opening polymerisation of ε-CL using Sn(oct)2 as a 
catalyst and hydroxyl compound as an initiator  
3.4 The structural characterisation of SPCL-HPG amphiphilic copolymers 
The SPCL polymers (hydrophobic segment) and SPCL-b-HPG copolymers (hydrophobic- 
hydrophilic copolymer) were characterized using 1H and 13C NMR spectroscopies and GPC. 
The 1H NMR spectrum of the SPCL in CDCl3 is shown in figure 3.2 and confirms the presence 
of the methylene protons of poly (ε-caprolactone) at 1.39, 1.66 and 2.32 ppm, respectively, for 
γ, β+δ, and α position respectively. In addition, peaks appeared at 0.83 ppm was assigned to 
the methyl protons of the core (TMP) suggesting the incorporation of the core within the PCL 
structure. The average length of each arm is calculated from the integration ratio of the 




Figure 3.2:1H NMR spectra of SPCL60-HPG90 in CDCl3 
In the 1H NMR spectrum of SPCL-b-HPG shown in figure 3.3, in addition to the peaks 
correspond to PCL, a multiplet at 3.60 ppm, was assigned to the CH and CH2 protons of HPG. 
 
  
Figure 3.3:1H NMR spectra of SPCL60-HPG90 in D2O 
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The molecular weights of polycaprolactone (SPCLs) were determined by 1H NMR 
spectroscopy and GPC  analysis  were very similar. Their values were almost identical to the 
theoretical values based on the core to monomer ratio, indicating a high level of control. 
Polydispersity indexes were relatively low and measured within the range of 1.28 to 1.47.  
  
Table 3.1: Summary of the estimated Mn values by GPC and 1HNMR spectroscopy, and the expected Mn 
of the hydroponic segment of star polymers (SPCL) 
 
The molecular weight characteristics of the amphiphilic star copolymers (SPCL-HPG) were 
also determined by 1H NMR spectroscopy and GPC analysis. On this occasion they appear to 
be large error based on the theoretical values. 
The GPC results were estimated using water as solvent/eluent and the values obtained were 
very low. The Mn values were smaller than the Mn calculated for the hydrophobic star block. 
This could indicate that the hydrophobic arms are constructed in water (not well solvated as 
the case was for PCL in THF solvent). So these Mn values are a guide only because of the 




Theoreticala 1H NMRb GPCc Đ 
SPCL15 5270 5000 7000 1.21 
SPCL35 12118 12500 14000 1.6 
SPCL60 20679 20000 21000 1.5 
Note: Numbers in subscript represents the number of repeat units (caprolactone) per 
polymer chain 
a. Calculation based on feed ratio of the monomer units to core 
b. As determined by integration of 1H NMR in CDCl3 
c. As determined by GPC (using tetrahydrofuran as the eluent) 
Đ:  polydispersity index 
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polyglycidol). For the same reason, in the 1H NMR spectra, integration of the hydrophilic 
region based on the constructed hydrophobic arms caused an overestimation in the molecular 
weights of the polymers. 
  
Table 3.2: Summary of the estimated Mn values by GPC and 1H NMR, and the expected Mn of the of the 
star co-polymers  (SPCL-HPG) 
 
3.5 One-pot Synthesis of hyperbranched polyglycerols (HPG)  
HPG polymers 6 are synthesized by adding strong base (potassium methoxide) to the core 1 
and propagation of the monomer 3 (glycidol) at 90 0C (Scheme 3.4).  
Initially, the reaction is initiated by deprotonating the hydroxyl groups of the core with 
potassium methoxide followed by slow addition of glycidol. The deprotonated species goes on 
to ring open the epoxide ring and form an alkoxide. This alkoxide then reacts with another 
glycidol monomer to form the desired HPG polymers, Scheme 3.5. However, non-cored HPG 
may also form if the glycidol monomer being deprotonated by any excess base or by the 
deprotonated core and act as an alternative core (Scheme 2.6). 
PyPCLn-HPGm Theoretical
a 1H NMRb GPCc Đ 
SPCL15-HPG90 11930 25000 4800 1.9 
SPCL35-HPG90 18778 32000 4500 2.2 
SPCL60-HPG90 27339 45000 4800 1.6 









Scheme 3.5: Reaction mechanism of the anionic ring opening polymerisation of polyglycerols 
 
 
Scheme 3.6: homo-polymerisation phenomena of polyglycerols  
3.6 Characterisation of hyperbranched polyglycerols   
The structure of HPG was characterized by 1H NMR, 13C NMR, FTIR spectroscopies and GPC. 
In the 1H NMR spectra, a broad multiplet at 3.70 ppm corresponding to the numerous different 
CH and CH2 protons in the polymer. In addition, there was broad multiplet observed  at 0.75 
ppm which was assigned to the methyl end group for the core suggesting incorporation of TMP 
into the polyglycidol. The molecular weight of the polymer was estimated by comparing the 
62 
 
integration of the CH/CH2 resonance to those from the core and found to be 37K Da. In the 
13C 
NMR spectra, resonaces from the polyglycerol, at 58–75 ppm, were observed in the HPG 
polymer. The IR spectra of HPG had a broad peak between 3260 and 3370 cm-1 in the spectra, 
assigned to the terminal OH groups in the polymer.The average molecular weight (Mn) of the 
HPG polymer obtained using aqueous GPC and 1H NMR spectroscopy are summarized in 
Table 3.3. Estimating Mn by 1H NMR spectroscopy assumes every monomer unit has a core. 
If this is not the case, and the polymer contains significant amount of homopolymer, the Mn 
will be overestimated. When comparing this to the Mn via GPC, it could appear that there is 
the case as the Mn value obtained from GPC analysis closer to the expected value based on 
core to monomer ratio.  
 Table 3.3: Molecular weight characterization of HPG polymers 
 
The degree of branching (DB) of grafted glycidols could not be calculated from 13C NMR 
resonances because the reasonace of linear (L) and terminal (T) carbons were indistinguishable.  
3.7 Aggregation of star copolymers  
During the synthesis of the amphiphilic star copolymers and HPG polymers, Luo et al described 
a similar synthesis of the star polymer targeted in this study. [46] However, this method 
involved a two-pot procedure but also reported a micellar structure that self-assembled in 
water. [46] Therefore, it was decided to study and maintain the self-assembly of the polymers. 
Critical micelle concentrations (CMCs) were assessed by fluorescence spectrophotometers 
Polymers Theoretical I NMRII GPCIII PDIIII 
TMP1-HPG90 20 37 18 3.6 
I: based on the core to monomer ratio  
II: as determined by integration of 1H NMR resonace in D2O 
III: As determined by GPC analysis (aqueous) 
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using pyrene as solvatochromic probe. In the presence of micelles, pyrene can move from the 
bulk aqueous phase (polar region) to the hydrophobic interior of the micelle. This accompanied 
by a red shift in the excitation spectrum of pyrene. A plot of the polymer concentrations vs. the 
shift in the pyrene emission is shown in figure 3.4. In this study, the CMC of SPCL60-HPG90 
was found to be 10-20 µg/mL.   
 
Figure 3.4: CMC determination of SPCL60-HPH90 
Having shown that the star copolymers could aggregate, the aggregation of the HPG (control) 
was also studied. The CMC of TMP-HPG90 was determined  to be 150 µg/mL, (figure 3.5), 
which was higher than the star copolymer. This is expected as the star copolymer has significant 
























Figure 3.5: CMC level of TMP-HPG90  
 The hydrodynamic diameter of the star copolymer (SPCL60-HPG90) and the TMP-HPG90 at 
the micelle concentration was measured using dynamic light scattering and found to be 170 
and 100 nm, respectively. This data confirms that both polymers do aggregate in water into 
certain size and shape.  
3.8 Selection of a suitable macromolecular guest 
The main aim of this study was to investigate the ability of the star copolymers to host large 
drug molecules. These guests can be peptides, DNA, proteins, etc.. In our group, a synthetic 
mimic of a hemoglobin. [47] This molecule is shown in figure 3.6.  
Although this molecule could reversibly bind oxygen over a number of cycles, it was not water 
soluble. Before this molecule could be applied as an artificial blood product it must be 
solubilizing in water. Attempts to make a water soluble version were successful, but the new 
molecule failed to bind to oxygen due to a water promoted oxidation of the Fe metal. Therefore, 
it was proposed that encapsulation of the original synthetic model (shown in scheme 3.7) within 
a hydrophobic environment. As such proposed to encapsulate the hemoglobin model within 






















Scheme 3.7: The structure of the organic soluble artificial blood polymer 
 
3.9 The synthesis of a porphyrin cored functionalized HBP (large molecule) 
The synthesis of the porphyrin cored HBP (the hemoglobin mimic) has been reported [92] and 
started for the synthesis of the porphyrin core. Tetrakis-(4-acetoxyphenyl) porphyrin, TAPP 8, 
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was synthesized from equimolar amounts  of pyrrole and 4-acetoxybenzaldehyde 7, which was 
synthesized via acetylating 4-hydroxy benzaldehyde using acetyl chloride. The synthesis is 
shown in scheme 3.8.  
 
Scheme 3.8: Synthesis of tetrakis (4-acetoxyphenyl) porphyrin 8 
The successful synthesis of TAPP 8 was confirmed by 1H NMR spectroscopy, which had 
doublets at 8.30 ppm and 7.52 ppm, corresponding to the ortho and meta-phenylic protons 
respectively. In addition, the β-pyrrolic protons of the porphyrin were observed as a singlet at 
8.85 ppm, while the two highly shielded inner porphyrin protons were characterized by a 
singlet at -2.87 ppm. Moreover, the successful synthesis of a porphyrin was further proved by 
UV/Vis spectroscopy. The distinct, sharp and intense Soret band was observed at 418 nm, 
together with four weaker Q-bands at 515 nm, 549 nm, 590 nm and 643 nm respectively.   
The monomer required for the porphyrin cored HBP was synthesized via the reaction of 3,5-
dihydroxybenzoic acid 9 and acetic anhydride, using sulfuric acid as an acid catalyst, scheme 
3.9. This yielded the desired 3,5-diacetoxybenzoic acid 10 in a yield of 80%. 
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The formation of 3,5-diacetoxybenzoic acid was confirmed by 1H NMR spectroscopy. The 
spectrum showed a proton resonance at 2.35 ppm, which corresponds to the six CH3 protons 
of the two acetoxy groups. In addition, a molecular ion peak at 237 g mol-1 was observed in the 
mass spectrum. 
 
Scheme 3.9: synthesis of monomer 13 from benzoic acid 14 
The hydrophobic HBP 11 could then be obtained, scheme 3.10. TAPP 8 was reacted with  3,5-
dihydroxybenzoic acid 11 in a molar ratio of 1:20, respectively. Specifically, firstly, the 
mixture was heated to 225 oC for 45 minutes before reducing the temperature to 180 oC and 
placing the reaction under reduced pressure for 4 hours. The hydrophobic HBP 11 was then 
precipitated from hot THF and cold methanol in a yield of 50%.  
The GPC analysis of TAPP-HBP 11 showed an Mn value of 18100 g mol-1 with a PDI value 
of 2.07. The low PDI indicated involvement of the core during that the polymerisation. The 
GPC trace showed only a broad peak for the hydrophobic HBP, free, non-functionalised 
porphyrin was not visable. The 1H NMR spectrum showed a proton resonace for the inner 
shielded porphyrin protons at -2.81 ppm and the pyrrolic β-hydrogens at 8.92 ppm. 
Furthermore, the success of the polymerisation was confirmed further through an observation 
of the characteristic singlets of the dendritic, linear and terminal proton resonace between 7.91-




Scheme 3.10: Reaction synthesis of the artificial blood polymer from acetoxy porphyrin 8 as the core and 
acetoxy monomer 11 
 
3.10 Encapsulation of a large hydrophobic macromolecular   
Having successfully synthesised the macromolecular (SPCL-HPG 5) and the macromolecular 
guest (TAPP-HBP 11), encapsulation of the large guest within the host was studied. UV/vis 
spectroscopy was utilised to quantify the concentration of the encapsulated guest (HBP 11) 
using the Beer Lambert equation. The first was to determine the molar extinction coefficient 
of TAPP-HBP 11 using acetone as the solvent. A linear plot of HBP 11 in organic solvent 
(acetone) was obtained and a ε value of 4.6 x 105 M-1 was determined. 
Encapsulation of the hydrophobic TAPP-HBP 11 was conducted using star copolymers with 
different chain length for the PCL arms, but the same size of HBP capping units (fixed at DP 
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=90). Complexes were formed using 10 mg/mL of each host polymer and excess of the guest 
TAPP-HBP 11. A methanol solution of the polymer was then mixed with an acetone solution 
of the hydrophobic. The solvents were evaporated to yield a purple/brown solid, which was 
dissolved in distilled water.  Insolubilized hydrophobic, guest TAPP-HBP 15 was removed by 
filtration, and the absorbance measured by UV/Vis spectroscopy. Similarly, the control 
(hydrophilic hyperbranched polymer) was complexed with the hydrophobic HBP guest 
molecule.  
The Soret band for guest TAPP-HBP 11 shifted from 417 to around 424 nm upon encapsulation 
for all of the polymers, indicating that solubilisation was successful, see table 2.4. A steady 
increase in the amount of guest encapsulated HBP 11 was observed as the length of the polymer 
arms increased. For example, the star copolymer which has 60 caprolactone units per arm 
(SPCL60-HPG) has encapsulated two times more of the guest TAPP-HBP 15 than the SPCL15-
HPG with 15 caprolactone units.  
 











TMP1-HPG90 0 90 0.56 3.61E-06 417 424 
SPCL15-HPG90 15 90 0.26 1.73E-05 417 424 
SPCL35-HPG90 35 90 0.38 2.53E-05 417 424 
SPCL60-HPG90 60 90 0.49 3.26E-05 417 426 
i degree of polymerization of caprolactone per arm 
ii degree of polymerization of glycidol per arm 




The control HPG could solubilise some of the guest TAPP-HBP 11 but the amount was very 
small, figure 3.9. This is surprising as the host HPG does not have space, however, it does 
aggregate (as it was approved earlier using pyrene as probe). Thus, it was proposed that the 
host HPG aggregate around the hydrophobic guest and hence offered solubilisation to the guest, 
figure 2.11, a. The encapsulation of the macromolecular guest with the star copolymers also 
happen due to aggregation, but since the star copolymers have great hydrophobic segment it 
could aggregate into certain shape to offer greater solubilisation for the guest, figure 3.11, b.  
 
Figure 3.6: Trend to show the increase in the concentration of the encapsulated HBP 11 within different 

























Figure 3.7: schematic representation showing where the encapsulation of the macromolecular guest 
(TAPP-HBP 15) with a) HPG and b) star copolymer happen  
 
3.11 Summary  
In summary, star copolymers based on polycaprolactone and polyglycidol (SPCL-HPG) were 
synthesised successfully via one-pot procedure using ring opening polymerisation. Three star 
copolymers (SPCL-HPGs) were prepared with different chain length and similar size of the 
capping group (SPCL15-HPG90, SPCL35-HPG90 and SPCL60-HPG90) in order to study the 
effect of the chain length upon encapsulating large molecule. The structures of the star 
polymers were confirmed by NMR spectroscopy and GPC. Hydrophilic HPG polymer was 
synthesised via ring opening polymerisation as the only control system of the proposed drug 
delivery system. The aggregation of the start copolymers and the control was approved by 
fluorescence techniaue using pyrene as a probe. The hydrodynamic diameter size for the star 
copolymers and the control  was determined at their respective critical micelle concentration 
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(CMC) via  DLS which was in the range of 100 to 200 nm. A model macromolecular guest, a 
synthetic mimic of hemoglobin (TAPP-HBP 11), was synthesised successfully and has been 
encapsulated within the star copolymers and the control system. Significant amount of the guest 
was loaded within the star copolymers than it was for the control system. The poor 
encapsulation of the guest within the control (HPG) thought to be related to the aggregated 
structure of the polymer; HPG does not have hydrophobic segment that can form micelle 
structure with large hydrophobic domain to encapsulate great amount of the guest as it was 
seen for the star copolymers. So, the star copolymers was deemed to be a solution for improving 
the aqueous solubility of large molecule. This delivery system could be a suitable carrier for 
peptide or other large biomolecules only if the chain of its hydrophobic segments been 
functionalised. This could be achieved by synthesising a functionalised caprolactone monomer 










4. Porphyrin cored star copolymers for photodynamic therapy 
Result and Discussuio  
4.1 Synthesis and characterisation of porphyrin photosensitizers  
The synthetic methods for generating porphyrins are generally result in low yielding. However, 
their synthesis can be achieved using inexpensive starting materials and is generally 
straightforward. In commonly, the synthesis of porphyrins typically requires the reaction of 
stoichiometric amounts of pyrrole and an aldehyde of choice to give the appropriate 
substitution at the meso positions, which are labelled with the numbers 5, 10, 15 and 20 in 
Scheme 4.1. 
 
Scheme 4.1: Synthesis of tetraphenylporphyrin TPP 
 
Porphyrins are UV-active molecules characterised by a very intense Soret emisson band at 
about 410 nm and four lower energy Q-bands. The lowest energy Q-band at about 650 nm, 
which is associated with absorptivities in the infrared to the thousands, is the transition of 
interest for PDT. In addition, porphyrins have been linked with highly efficient formation of 
reactive oxygen species (ROS) and affinity for tumour sites. [69] 
In this chapter, two porphyrin molecules were chosen to fulfil the aim of developing a polymer-
based system for PDT. The selected porphyrins were tetrakis(4-hydroxyphenyl)-porphyrin 
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(THPP) 12 and tetrakis(3,5-dihydroxyphenyl)-porphyrin (TDHPP) 13, as shown in Figure 4.2; 
these porphyrins contain hydroxyl groups, which facilitate the polymerisation. According to 
the literature, [70] THPP and TDHPP molecules have a low phototoxicity D37 (dose required 
to reduce cell survival by 37%) of 0.02 and 7.2 µM, respectively and a dark toxicity of 3.1 and 
15 µM, respectively, using the HeLa cell line. Constructing appropriate polymeric delivery 
systems from these porphyrins will allow the investigation of the effectiveness of their nature 
as a dual system for PDT and chemotherapy. Using these porphyrins as initiators/cores for 
amphiphilic star polymers, different arms will be obtained and hence the effect of arm length 
upon the aggregations will be highlighted. 
 
Figure 4.1: Potential porphyrin derivative to be used as a core in drug delivery systems for PDT 
applications THPP 12 and TDHPP 13 
4.1.1 Tetrakis(4-hydroxyphenyl)-porphyrin (THPP 12) 
THPP 12 was successfully synthesised from 4-hydroxybenzaldehyde  and pyrrole following 
the method by Rothermund and Adler–Longo method. [49] The aldehyde and pyrrole were 





Scheme 4.2: Synthesis of THPP 20 
Regarding the 1H NMR spectrum, the internal N–H proton resonance of THPP were observed 
in the highest field region (-2.9 ppm) because of the ring current interaction. Resonances 
corresponding to the O–H and pyrrole or phenyl protons were observed in the low field region 
of 10.01 ppm (O–H) and 9.1 ppm (β-H–pyrrole), respectively. Resonace at 7.3–8.1 ppm (ortho 
and meta H–Ph) were also observed. 
The FT-IR spectrum showed an absorption band of strong intensity located at 3420 cm-1, which 
was attributed to the O–H stretching vibration. The absorption at 3311 cm-1 was assigned to 
the stretching and bending vibrations of N–H, which is a characteristic absorption of free base 
porphyrins. The UV/vis spectra of THPP in methanol displayed a very intense Soret band at 
417 nm and four Q-bands at 512, 550, 585 and 640 nm. The molar extinction coefficient of 
THPP in methanol was found to be 4 × 106 L mol-1 cm-1. 
Scheme 4.4 shows the mechanism of synthesis THPP 12. The electron-dense carbon on the 
pyrrole attacks the electrophilic carbon on the protonated aldehyde to form the intermediate 14 
and then compound 15. A second equivalent of pyrrole then attacks the sp3 carbon of compound 
15, resulting in the loss of water and the formation of intermediate 16 and then compound 16. 
This is followed by a further electrophilic substitution reaction involving the pyrrole unit and 





Scheme 4.3: Mechanism of synthesis of THPP 12 
78 
 
4.1.2 Tetrakis(3, 5-dihydroxyphenyl)-porphyrin 
TDHPP 13 was synthesised in a two-pot reaction procedure, as illustrated in Scheme 4.5. The 
first step involved the synthesis of tetrakis(3,5-dimethoxyphenyl)-porphyrin (TDMPP) 18, 
which was achieved by refluxing equimolar quantities of 3,5-methoxybenzaldehyde and 
pyrrole for 30 minutes. The second step of preparing the desired porphyrin 13 was achieved by 
the demethylation of TDMPP using boron tribromide as the demethylation agent. 
 
Scheme 4.4: Synthetic method for TDHPP 13 
The UV/vis absorption spectrum of TDMPP 18 confirmed the presence of the porphyrin 
displaying a Soret band at 420 nm and four Q-bands at 513 nm, 548 nm, 586 nm and 643 nm. 
The methoxy porphyrin 18 was also confirmed by mass spectrometric analysis, which had a 
molecular ion peak at 855. Additionally, there was a large singlet at 3.98 ppm from the methoxy 
protons and a peak at -2.9 ppm for the porphyrin ring  N–H protons in the 1H NMR spectrum. 
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In the preparation of TDHPP 13 from TDMPP 18, the methoxy porphyrin was dissolved in 
anhydrous dichloromethane and stirred under nitrogen for 10 minutes, after which boron 
tribromide was added dropwise, turning the solution green. Boron tribromide is a strong Lewis 
acid that interacts with the lone pair of the methoxy oxygen, ejecting a bromide ion that attacks 
the methyl group, which leaves as methylbromide, as shown in Scheme 4.6. Hydrolysis then 
occurs, replacing the bromides with hydroxyl groups, and the boron then leaves as boric acid 
to yield the deprotected product and hydrogen bromide. 
 
Scheme 4.5: Generic mechanism of demethylation by BBr3 
The reaction was performed at room temperature with stirring for about 5 hours, after which 
any unreacted boron tribromide was quenched with the slow addition of water. The acidic 
reaction mixture was neutralised with sodium hydrogen carbonate solution and extracted with 
ethyl acetate. The crude product indicates initial success by a dramatic change in solubility; the 
starting material (TDMPP 18) is soluble in dichloromethane whereas the product was not. The 
protection was confirmed by 1H NMR spectroscopic analysis, which showed the loss of the 
methoxide proton resonance at 3.98 ppm, and by mass spectroscopy, which gave a molecular 
ion peak at 743. The product was also confirmed by FTIR spectroscopy where a broad peak at 
3400 cm-1 indicated the presence of hydroxyl groups. 
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4.2 Synthesis of porphyrin-cored hyperbranched polyglycerols (HPG) 
Having successfully synthesised and characterised the cores/initiators, the control systems, 
porphyrin-cored polyglycerols, were synthesised next. Porphyrin molecules (THPP 12, 
TDHPP 21) were used for the anionic ring-opening polymerisation of glycidol and produced 
porphyrin-cored hyperbranched polyglycerol (porphyrin–HBP). The advantage of the covalent 
incorporation approach is that the porphyrin stays at the central position of the hydrophobic 
interior and is not retained easily. The synthesis utilised 50 equivalents of glycidol monomer 
per hydroxyl group of the core to yield HPGs with similar size of HPG per arm in order to 
determine which Porphyrin-HPG polymer is best for effective PDT. Scheme 4.6 shows the 
reaction scheme for THPP-cored polyglycerols (THPP–PG). 
The core and diethylene glycol dimethyl ether (diglyme) were added to an oven-dried two-neck 
bottom flask and heated to 90 °C under nitrogen atmosphere until complete dissolution of the 
porphyrin had occurred. Potassium methoxide was then added and an instant colour change 
from red purple to green was observed, indicating the deprotonation of the core. A mixture of 
Scheme 4.6: Reaction scheme of synthesizing THPP-cored polyglycerols; TDHPP-PG was synthesised in the 
same manner  
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glycidol and diglyme (3:1) was slowly injected into the reaction flask with the aid of a syringe 
pump over a period of several hours. The glycidol was added slowly to prevent explosion. The 
polymer structure was characterised by 1H NMR spectroscopy to indicate the successful 
synthesis of the hyperbranched polymer. Two significant regions were observed in the 
spectrum. One was in the aromatic region at 7.8–8.4 ppm for the porphyrin (phenolic and 
pyrrolic protons). The second was at higher field, with a multiplet broad peak at 3.2–4.2 ppm 
for the CH, CH2 and OH groups of the polyglycidol backbone. 
Fourier transform infrared (FTIR) spectroscopy was also used to confirm the porphyrin–HBP 
structure. The spectrum displayed a broad peak at 3320 cm-1 for the OH groups and a peak at 
2845 cm-1 for the C–H protons and a C–O peak 1630 cm-1. 
The molecular weight of the hyperbranched polymer was characterised by gel permeation 
chromatography (GPC) and compared to the theoretical values and 1H NMR spectroscopy data, 
as shown in Table 4.1 
Table 4.1: Summary of the average molecular weight of porphyrin-cored polyglycerols using different 
techniques 
Core of HPG Theoretical NMRa GPCb  Đc 
THPP 15479 39000 14000 1.5 
TDHPP 30343 61000 42000 2.3 
a As determined by integration of 1H NMR resonance in D2O 
b As determined by GPC analysis (aqueous) 
c Polydispersity index 
 
 
The theoretical molecular weight (Mn) was calculated by multiplying the ratio of the monomer 
(50) by the number of hydroxyl groups of the cores (four OH groups for THPP and eight for 
TDHPP) and by the molar mass of the glycidol (74.08 g mol-1) before adding the molar mass 
of the core (679 g mol-1 for THPP and 743 g mol-1 for TDHPP) to yield 15479 Da for THPP–
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PG and 30343 Da for TDHPP–PG. The theoretical Mn would match the Mn obtained by GPC 
or 1H NMR only if the polymerisation is highly controlled. However, this is unlikely to occur 
with the anionic ROP polymerisation of glycidol. Thus, a discrepancy between the theoretical 
Mn and those obtained by either 1H NMR or GPC is very likely. 
The Mn obtained from GPC (aqueous) was approximately 14 KDa for the THPP–PG and 41 
KDa for the TDHPP–PG (relative to linear polyethylene glycol (PEG or PEO) with a 
polydispersity of 1.5 and 2.3 in aqueous solution),  respectively. This was quite close to the 
theoretical Mn values. 
Meanwhile, the Mn obtained by 1H NMR spectroscopy analysis for both polymers were higher 
than both the theatrical Mn and the Mn by GPC; this is because 1H NMR spectroscopy cannot 
differentiate between polymers with or without a core. Interpretation of the 1H NMR 
spectroscopy data overestimates the molecular weight by assuming that every monomer has a 
core, whereas the GPC underestimates the Mn owing to the error derived from calibrating the 
instrument with a linear polymer such as PEG or polystyrene. 
The Mn obtained by 1H NMR and UV spectroscopy were closer to the theoretical Mn than that 
obtained by GPC but, in general, there was no regular trend observed between the Mn obtained 
using different techniques owing to the uncontrolled polymerisation of glycidol.  
4.3 Porphyrin star poly(Ɛ-caprolactone)-polyglycerol copolymers 
The synthesis involved a two-step one-pot reaction as was employed for the non-porphyrin-
cored star copolymers. First, the porphyrin core and the catalyst (Sn(oct)2 ) were reacted with 





Scheme 4.7: Ring-opening polymerisation of porphyrin initiator with e-caprolactone monomer 
A small sample was withdrawn and analysed by 1H NMR spectroscopy to ensure that the 
photoactive porphyrin initiator was incorporated into the star polymer before proceeding to the 
second step. The 1H NMR spectra showed the typical signals of PCL whereas the porphyrin 
protons were not observed. This confirmed that the porphyrin did not get incorporated during 
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the polymerisation procedure. This could be owing to conjugation of the oxygen lone pair in 
to the porphyrin making it unreactive (Figure 4.2). Therefore, a spacer was attached between 





4.4 Synthesis of 
porphyrin initiators 
Porphyrins are known to be highly conjugated molecules; consequently, delocalisation reduces 
the reactivity of the lone pair of the hydroxyl group, preventing it from reacting with some 
monomers. For this reason, the anionic polymerisation of caprolactone initiated by porphyrin 
was not feasible and hence increasing the reactivity of porphyrin molecules was crucial for 
polymerisation to occur. Attaching a spacer between the oxygen and the porphyrin could break 
the conjugation and hence allow the polymerisation of Ɛ-caprolactone to occur. 
4.4.1 Acetonide–porphyrin 
Our initial idea for breaking the conjugation of porphyrin was to add bis-MPA (2,2-
bis(methylol)propionic acid) 20, scheme 4.9. Adding a spacer with two active sites will also 
Figure 4.2: delocalization of the hydroxyl lone pair with the aromaticity 
of the porphyrin ring 
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increase the number of arms of the star polymer, which is a desired feature in terms of 
maximising the number of branching arms. 
The preparation of diol 25 is shown in Scheme 3.8 and starts with the protection of the diol 
group of 2,2-bis(hydroxymethyl)propionic acid 20 by reaction with 2,2-dimethoxypropane 19 
and a catalytic amount of p-toluenesulfonic acid monohydrate (TsOH) in dry acetone to afford 
21. Anhydride 22 was then synthesised by self-condensation of 21 in chloroform using N,N′-
dicyclohexylcarbodiimide (DCC). The crude anhydride 22 was purified from excess DCC and 
the N,N′-dicyclohexylurea (DCU) byproduct by precipitation into hexane to afford an 
essentially pure product. Coupling of 21 with the phenolic groups of THPP 12 was successfully 
accomplished, as confirmed by mass spectrometry with an MH+ of 1304, using 1.5 equivalents 
of 22 per hydroxyl group to obtain a 90% yield of 24. The esterification reaction was carried 
out in a 1:3 mixture of pyridine and chloroform using DMAP (4-(dimethylamino) pyridine) as 
the acylation catalyst. However, there was a problem with the deprotection step using 
DOWEX-50-X2 resin or sulfuric acid; the phenolic ester linkage between the porphyrin and 
the acetonide was hydrolysed instead of the dimethoxy end group. The reaction of the final 
step to obtain compound 25 was time consuming and requires further exploration using 
different concentrations of DOWEX or different agents. Therefore, another spacer with a 








4.4.2 Spacer–porphyrin (S-porphyrin) 
The syntheses of S-THPP 26 and S-TDHPP 27 were achieved easily through the reaction of 
porphyrin and 1,3-bromopropanol with K2CO3 and 18-crown-6 in dry DMF (Scheme 4.10). 
The reaction was vigorously stirred under reflux overnight and the completion of the reaction 
was monitored by TLC. The identity of the porphyrin initiator was confirmed via mass 
spectrometry (M+H+ of 911 and 1215 for S-THPP 26 and S-TDHPP 27, respectively). The 1H 
NMR spectrum also confirms the formation of the S-porphyrin initiator, with the notable 
presence of the spacer proton resonance. 
 




4.4.3 Synthesis of spacer–porphyrin-cored hyperbranched polyglycerols 
Following the successful synthesis of spacer–porphyrin molecules, hyperbranched 
polyglycerols S-THPP-HPG 28 and S-TDHPP-HPG 29 (Figure 4.3) were synthesised in the 
same manner as THPP-HPG. 
 
 
Figure 4.3: Structures of S-THPP-HPG 28 and S-TDHPP-HPG 29
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The molecular weight of the hyperbranched polymer was characterised by gel chromatography 
(GPC) 
 
 and compared to the theoretical and 1H NMR data, as shown in Table 4.2. 
Table 4.2: Summary of the average molecular weight of porphyrin-cored polyglycerols using different 
techniques 
 Theoretical NMRa GPCb PDI 
S-THPP1-HPG50 28 15711 50000 19000 1.5 
S-TDHPP1-HPG50 29 30806 15000 8500 2.3 
a As determined by integration of 1H NMR resonance in D2O 
b As determined by GPC analysis (aqueous) 
 
4.5 Synthesis of porphyrin star poly(Ɛ-caprolactone)-polyglycidol copolymers 
(SPPCL-HPG) 
The synthesis of SPPCL-HPG involved a two-step one-pot reaction, as shown in Scheme 4.11. 
First, the spacer–porphyrin core and Sn(oct)2 as the catalyst were reacted with ε-CL monomer 
via a ring-opening polymerisation at 130 °C for 24 hours. The molar ratio of the core to the 
monomer was varied to make a family of star polymers. Before proceeding to the second step, 
a small sample was withdrawn for analysis. Table 4.3 shows the molecular weight of the initial 
star polymers obtained via different analytical techniques. 
Table 4.3: Molecular weight of the initial star polymers determined by different techniques 
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The second step in the synthesis of the star copolymers SPPCL-HPG (31 and 33) involved the 
addition of the HPG units. This was done by using the SPPCL (30 or 32) as a core unit for the 
anionic ring-opening polymerisation of glycidol. The polymer was precipitated from methanol 
into cold acetone and dialysed (with a 12 KDa molecular weight cut off) against water for 48 
hours. The material obtained was dried and characterised to determine the molecular weight 
and structure of the final star polymers. 
The 1H NMR spectra of the star copolymers showed the presence of both blocks, suggesting 
the success of the reaction. However, the protons of the hydrophobic core (SPPCL) were 
collapsed in water and hence integrating the hydrophilic protons per hydrophobic block did not 
afford a reliable estimation of the Mn values. Aqueous GPC for the star copolymers could not 
be used to estimate the Mn because of the nature of the polymer in aqueous media, which forms 
aggregates (diameter of less than 200 nm), and the size obtained will be underestimated. 
 
Table 4.4: Molecular weight of the star copolymers determined by different techniques 
1st step crude 
(Core : monomer) 
/ arm 
Mn a Mn b Mn c PDI 
S-TDHPP1-PCL10 32 1:10 10337 23000 19000 1.2 
S-TDHPP1-PCL35 32 1:35 33165 70000 40000 1.1 
S-THPP1-PCL40 30 1:40 19173 22000 22000 1.0 
a Therortical Mn 
b As determined by integration of 1H NMR resonance in CDCl3 
c As determined by GPC analysis (THF) 
2nd step crude 
(Core : 
glycidol) / arm 
Mn a Mn b Mn c PDI 
S-TDHPP1-PCL10-HPG35 33 1:35 31057 35000 27000 1.4 






Scheme 4.10: Synthesis of S-THPP- cored star copolymer (SPPCL-HPG 31) 
S-THPP1-PCL40-HPG60 31 1:60 36933 90000 51000 1.0 
a Therortical Mn 
b As determined by integration of 1H NMR resonance in D2O 
c As determined by GPC  analysis (aqueous) 
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4.6 Micelle formulation  
Polymeric micelles made from amphiphilic copolymers can spontaneously form in aqueous 
media. This thermodynamically favoured aggregation occurs above the so-called critical 
micelle concentration (CMC). Micelles with a low CMC are preferred as they have a high level 
of thermodynamic stability. Micelles with a low CMC can be obtained by increasing the 
hydrophobic segment of the amphiphilic copolymer. Therefore, the amphiphilic star 
copolymers decribed are composed of many hydrophobic segments are thus expected to form 
micelles at a lower CMC compared to hyperbranched polyglycerols (porphyrin-HBPs), which 
do not have very large hydrophobic segments and which have been proven to aggregate in the 
previous chapter. In this project, the CMCs of the star copolymers and HPG were examined 
using dynamic light scattering (DLS) and fluorescence to give an indication of the different 
aggregated structures. 
4.6.1 Dynamic light scattering 
DLS has been found to be just as sensitive as fluorescence spectroscopy in the determination 
of the CMC. Simultaneously, DLS can determine the hydrodynamic diameter of the aggregated 
structures. To determine the CMC of the polymers, aqueous solutions within the concentration 
range of 1 × 10-2 mg mL-1 and 1 mg mL-1 were prepared. 
The CMC of the star copolymer (S-THPP1-PCL40-HPG60 31, 51 KDa) was determined in the 
first instance as 125 µg/mL (5.8 µM), which is in agreement with the CMCs reported for other 
amphiphilic polymeric micelles. At low concentrations reading of 0.0 was observed because 
aggregated structures were not formed. At higher concentrations of polymer, two different 
aggregated structures were found, first at 125 µg/mL and the second at 300 µg/mL with 
hydrodynamic diameters of 250 and 360 nm, respectively. The smaller hydrodynamic diameter 
has been assigned as micelles but the molecules with a diameter greater than 200 nm are 
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thought to be vesicles or rod structures. Interestingly, the porphyrin-cored hyperbranched 
polymer (S-THPP-HPG 28, 20 KDa) has a smaller hydrodynamic diameter but a similar CMC 
level (125 µg/mL) to the star copolymer (S-THPP1-PCL40-HPG60 31, Figure 4.4 b). HBP 
(THPP-HPG, 14 KDa) has a higher CMC level at around 1.3 mg/mL (93 µM, Figure 4.4 c), as 
expected. The star copolymers behaved differently to the HPG polymers; two different 
aggregated structures were observed for the star copolymers while there was only one for the 
HPG polymers. 
 
Figure 4.4: Plots of the hydrodynamic diameter obtained for various concentrations of a) S-THPP1-PCL40-
HPG60 31, b) S-THPP-HPG 28 and c) THPP-HPG in deionised water. 
95 
 
4.6.2 Fluorescence technique 
CMCs were also determined by fluorescence measurement using pyrene as a probe. [12] 
Pyrene inside micelles is in a hydrophobic microdomain. This is different to the aqueous 
environment. Consequently, a red shift of pyrene’s emission is observed in the excitation 
spectrum when the aggregation occurs the pyrene enters the hydrophobic micelle. 
The CMC of S-THPP1-PCL40-HPG60 31 as determined by fluorescence (67 µg/mL) was 
slightly lower than that obtained by DLS (120 nm). As with DLS, another structure was 
observed at a higher concentration of 300 µg/mL, Figure 4.5 a. There was no significant 
difference between the CMC level obtained for the two different techniques, suggesting reliable 
data. Table 4.5 show a summary of the CMC level obtained for all the polymers along with 
their respective hydrodynamic diameters as obtained by DLS. The results showed that all the 
HPG polymers have higher CMC level than star copolymers because the lack of hydrophobic 
segment within their structure.  






S-THPP1-PCL40-HPG60 31 70 200 
S-THPP-HPG 28 150 90 
THPP-HPG 300 50 
S-TDHPP1-PCL10-HPG35 33 200 200 
S-TDHPP1-PCL35-HPG35 33 170 200 
S-TDHPP-HPG 29 350 100 






Figure 4.5: Plots of the intensity ratio of I1/I3 against log concentration of a) SPPCL-HPG 41, b) S-THPP-
HPG 31 and c) THPP-HPG in deionised water.   
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4.7 In vitro study (cytotoxicity and phototoxicity) 
Having successfully synthesised and characterised porphyrin star copolymers and control 
polymers, the cell viability, including cytotoxicity and phototoxicity, was evaluated in human 
breast adenocarcinoma MCF-7 and EJ bladder cells. 
4.8 Cell work using MCF-7 
The human cancer cell line MCF-7 was maintained in tissue culture in a Petri dish at 37 °C in 
a 5% CO2 atmosphere in a biosafety cabinet. Compounds that were considered for the PDT 
first were:  S-THPP1-PCL40-HPG60 31 and S-TDHPP1-PCL10-HPG35 33. For effective 
PDT, a low concentration of the PSs and a low dose of light are desirable. Concentrations were 
calculated with respect to the porphyrin using Beer–Lambert analysis. Therefore, 
concentrations started at 150 µM for compound 31 and 140 µM for compound 33 in terms of 
porphyrin concentrations. For the phototoxicity studies, two light doses were used: 5 and 10 
mW cm-2. 
As discussed in the introduction, the ideal PS should not harm healthy cells (when not exposed 
to light). Therefore, the cells treated with the PSs at their highest concentration should exhibit 
complete death when exposed to the specific light. As desired, both compounds exhibited little 
dark toxicity (cell viability > 90%) at their highest concentrations. However, phototoxicity was 
not as expected: 60% of cells were still viable at a high concentration of  compound 31 whereas 




Figure 4.6: % Cell viability of the phototoxicity SRB assay of MCF-7 cells treated with different 
concentrations of a) compound 41 and b) compound 33 at different LED doses of zero (dark), 5 minutes 
LED (0.84 J/cm2) and 10 minutes LED (1.65 J/cm2). 
One reason for the poor phototoxicity is that the PS did not absorb the light and failed to 
produce ROP; this could be due to the media. Therefore, the experiment was repeated without 
media prior to light treatment. However, removing the media from the cells for a short period 
(5 or 10 minutes) may affect the growth of the cells so a control experiment was carried out to 
determine whether removing the media from the non-treated cells (10 minutes) affects the cell 
growth. The results obtained from this control experiment indicated that removing the media 

















































Figure 4.7: % Cell viability of the dark toxicity SRB for of MCF-7 cells with and without removal of the 
media for 10 minutes 
The dark toxicity of the compounds was studied again at different concentrations. The results 
showed that all the compounds are considered safe (Figure 4.8). Without any light irradiation, 
the toxicity of compound 31 and compound 33 at high concentrations (900 and 400 µM, 
respectively) was negligible; the overall cell viability was higher than 80%. 
The phototoxicity was then studied at two different light doses (5 minutes LED and 10 minutes 
LED) for both compounds. The results for the 10 min LED light dose (Figure 4.9) show 
significant phototoxicity (LD50) for compound 31 and compound 33 at 14 and 50 µM, 
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Figure 4.8: % Cell viability of the dark toxicity SRB assay of MCF-7 cells treated with different 
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4.9 MTT assay using EJ cell lines 
Initially, compounds were divided into two groups based on the core used; Table 3.5 provides 
details of the labelling used. THPP 12 and TDHPP 13 were labelled as th and td, respectively, 
the polymers cored with THPP were labelled with odd italic numbers while polymers cored 
with TDHPP were labelled with even italic numbers, as shown in Table 4.6.  
 Table 4.6: Compounds labelling  
 
The dark toxicity of each set was initially studied by MTT assay (a colorimetric assay that 
assesses cellular metabolic activity) and a bladder cell line (EJ). From the graph shown in 
Figure 4.11, it clear that THPP and THPP-HPG have significant dark toxicity. Interestingly, 
the toxicity is markedly decreased if a spacer (S-THPP-HPG) or a polymer (S-THPP-PCL40-
HPG60 31) is added between the porphyrin and the hyperbranched polyglycerol HPG. 
 










































The dark toxicity of the THPP was further investigated over a range of concentrations (0.1–
100 µM). The results showed that THPP killed around 70% of the cells at concentrations higher 
than 10 µM, as shown in Figure 4.11. 
 
Figure 4.11: Dark toxicity of THPP at different concentrations in EJ cell line 
 
In contrast, none of the molecules possessing the porphyrin with eight hydroxyl groups 
(TDHPP) exhibited any dark toxicity at 100 µM, figure 4.12. Comparing these results to those 
reported in the literature, THPP had a D37 (dark toxicity where 37 refers to the dose required 
to reduce cell survival to 37%) of 0.3 µM using a human tumour cell line (HeLa) whereas 




























Figure 4.12: Dark toxicity of TDHPP molecule and TDHPP-cored polymer at 100 µM 
For use in PDT, the phototoxicity of both sets was studied at various concentrations (TH-set: 
0.1–10 µM, TD-set: 0.1–100 µM). It was decided to study the light toxicity of the TH-set at 
low concentrations (0.1–10 µM) because it has dark toxicity at very low concentrations. The 
results revealed that compounds 1 and 3 have a light toxicity LD50 (dose required to reduce cell 
survival to 50%) of 1 µM and 5 µM, respectively, figure 4.13. Both compounds killed the cells 
completely at 10 µM. In contrast, compound 5 exhibited little light toxicity at 10 µM and a 
higher concentration might be effective for PDT. 
 


















































However, the TD-set showed no significant phototoxicity at 10 µM. The only exception was 
the control (TDHPP), which had an LD50 of 8.5 µM, as shown in Figure 3.14. With increasing 
concentration, recorded LD50 values were concentration of 40 µM and 100 µM for S-TDHPP-
HPG and TDHPP-HPG, respectively. 
 
Figure 4.14: Phototoxicity of TDHPP-set compounds using EJ cell line at a light dose of 10 mW/cm2 
4.9.1 Intracellular localisation 
The intracellular localisation of the molecules (THPP-set and TDHPP-set) into EJ (bladder 
carcinoma) cells was imaged by confocal microscopy, table 3.5 and 3.6. Both THPP and 
TDHPP molecules (naked porphyrin) diffused within the cell. Porphyrin-HPGs (compounds 1, 
2, 3 and 4) also diffused within the cells but as the spacer was added the diffused fluorescence 
decreases. The porphyrin-PCL-HPGs star copolymers (compounds 5 and 6) showed no 
diffusion into the cells at 10µM. Higher concentration of the star copolymers is required for 




























Table 4.7: Table to show the confocal images for naked porphyrin (THPP (th)), compound 1 (THPP-
HPG), Compound 3 (S-THPP-HPG 33) and compound 5 (SPPCL40-HPG60 41)  
 red overlay bright 
th    
1    
3    





Table 4.8: Table to show the confocal images for naked porphyrin (TDHPP (td)), compound 2 (TDHPP-
HPG), Compound 4 (S-TDHPP-HPG 34) and compound 5 (SPPCL10-HPG35 43)  
 red overlay bright 
td    
2    
4    







4.10 Summary  
In this chapter, star copolymers based on polycaprolactone and polyglycidol with porphyrin 
core were synthesied successfully for photodynamic therapy (PDT) application. Thus, the 
solubility of porphyrins in aqueous solution was enhanced significantly via covalent 
incorporation within aggregated water-soluble polymers. Two porphyrin molecules with 
hydroxyl end group were selected as a core these are: tetrakis(3,5-dihydroxyphenyl) porphyrin) 
(TDHPP), and tetrakis(4-(hydroxyphenyl)porphyrin (THPP). However, the reactivity of  
TDHPP and THPP was not good  for  the ring opening polymerization of caprolactone until a 
spacer was added. Thus, two star copolymers were synthesised from spacer-porphyrin (S-
THPP-PCL-HPG) and S-TDHPP-PCL-HPG). The control (porphyrin-HPG) were synthesised 
from porphyrins with and without spacer units. The particle size of all the aggregated polymers 
was then determined via DLS and found to be between 100-200 nm. The cytotoxicity and 
phototoxicty of  the star copolymers  (compound 31 and 33) were tested initially via SRB assay 
using MCF-7 cell line. The result showed that both of the polymers, compound 31 and 33, 
exhibited negligaible toxicity at concentration of 400 and 900 µM. The phototoxicity of these 
compounds were obvious at 14 and 50 µM, respectively. The cytotocity and phototoxicty of 
all the porphyrin cored polymers were inistigated further for their PDT behaviour via a simple 
MTT assay, using the EJ (bladder carcinoma) cancer cell line. The relative viability of the 
polymers and its controls in the dark were higher than 0.8 at 100µM except the THPP-HPG 
polymer which had a viability 0.2. Under light irradiation (10 mW/cm2), significant toxicity 
was observed at 1 µM for the free THPP and at 10 µM for the free TDHPP porphyrin. While 
phototoxicity of the polymers, considerable cell death was obvious at polymers concentration 
of 10 µM for the THPP cored polymers except the star copolymer, which did not show any 
significant toxicity at this concentration. The phototoxicity of TDHPP cored polymers were 
significant for TDHPP-HPG and S-TDHPP-HPG at 100 µM for and poor for the star copolymer 
108 
 
at same concentration. The intracellular localisation of the molecules porphyrin cored polymers 
into EJ cells was imaged by confocal microscopy. Both of the free porphyrin (THPP and 
TDHPP) molecules diffused within the cell at a concentration of  10 µM.  Porphyrin cored 
HPG polymers also diffused within the cells but as the spacer was added the diffused 
fluorescence decreases. The porphyrin-PCL-HPGs star copolymers showed no diffusion into 
the cells. Thus, porphyrin-cored HPG polymers were deemed to be promising photosensitizers 
for photodynamic therapy (PDT) rather than the star copolymers. Other photosensitizers (such 
as phthalocyanine and chlorine) could be functionalised with nucleophilic end group and used 
as core for ROP of glycidol for effective PDT. These compounds as effective photosensitizer 
could then be investigated further using different cell lines and assay. In vivo study would be 











5.0 Chemo-Photodynamic Combination Therapy 
Paclitaxel (PTX) is an anti-microtubule agent extracted from the trunk bark of the Pacific Yew 
tree, considered as one of the most effective chemotherapeutic drugs ever developed used 
against a variety of human cancers, such as ovarian, lung, and breast cancers. The active 
mechanism of PTX is to encourage and stabilise microtubule polymer and blocks cells in G2/M 
phases of the cell cycle and hence cause cell death. However, the major drawback of PXT is 
its low water solubility (~0.46 μM). Therefore, it is formulated in a mixture of 
polyoxyethylated castor oil (Cremophor EL) and dehydrated ethanol (50/50, v/v) under the 
trademark “Taxol”. However, Taxol has serious side effects, such as hypersensitivity reactions 
related to Cremophor EL [2]. Therefore, there is an urgent need for an alternative formulation 
of PTX that offers a prolonged infusion time, pre-treatments, and which has minmum or no 
side effects.  
Biodegradable and non-toxic nano-delivery systems are promising vehicles in drug delivery 
because they can protect the drug from degradation during circulation and, in turn, lower the 
drug toxicity, exhibiting improved pharmacokinetic profiles, and providing better patient 
compliance. Secondly, nanoparticle-based delivery systems enable preferential delivery of 
PTX into the target site due to the enhanced permeability and retention (EPR) effect.  
In this study, the targeted drug delivery systems porphyrin cored hyperbranched polymers and 
porphyrin cored star copolymers, are used to enhance the solubility of the hydrophobic drug 
PTX via hydrophobic interaction. Therefore, the potential of the porphyrin-delivery systems 
for the synergistic combination of PDT and chemotherapy for cancer treatments is investigated. 
PTX has a distinct absorbance band at 230 nm attributed to the three benzene rings within its 
structure (Figure 5.1) which is observed by UV/vis spectroscopic techniques using different 
organic solvents such as DCM, acetone, DMSO, and others. Therefore, UV/Vis spectroscopy 
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Figure 5.1: The Chemical structure of paclitaxel 
 
PTX is insoluble in PBS 7.4 but is readily soluble in methanol, hence a combination was used 
containing methanol and PBS in a 3:7 ratio. PTX showed a very good linear response with 
absorbance and concentration over the rang of 0-20 µg/ml (Table 5.1). 
Table 5.1: Characterisation of PTX in MeOH: PBS (3:7) 
 
Parameters PTX 
λmax (nm) 230 
Lambert-Beer’s law range (µg/mL) 0-20 
Correlation coefficient (R2) 0.997 




5.1 Kinetic/Thermodynamic Solubility of PTX in water 
Solubility is a key parameter in pharmaceutical research and development and is related to 
pharmacokinetics, pharmacodynamics, and toxicodynamics. PTX is composed of several 
hydrophobic substituents, which make it a highly lipophilic compound with an aqueous 
solubility of less than 0.01 mg/mL (11.7µM). [13–15]  
In this part of the study, the water solubility of PTX was determined using different approaches: 
solid PTX dissolved directly in water (method a), and solid PTX dissolved in organic solvent 
(method b), in which upon solvent evaporation water is added. While the Kinetic Solubility of 
PTX was determined by dissolving PTX in 100% DMSO and, from that, 1% of DMSO solution 
was extracted.   
In both cases, the aqueous solubility of PTX was determined by UV/vis after filtration with a 
0.2µm syringe filter to remove the insoluble PTX. The results obtained for the water solubility 
of PTX using different approaches are summarized in Table 5.3. The water solubility of PTX 
by the thermodynamic method a and kinetic approach was very low and with good agreement 
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Figure 5.2: Beer Lambert Plot of PTX in MeOH: PBS (3:7) 
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to the literature value. In contrast, the PTX aqueous solubility obtained by the thermodynamic 
method b was higher than the literature ranges. [13-15] Initially, it was thought that the higher 
solubility could be explained as the PTX lattice is broken completely in methanol and upon 
solvent evaporation, PTX forms a new allotrope that is more easily dissolved in water. 
Therefore, the encapsulation of PTX in the polymeric micelles was studied using the solvent 
evaporation method (thermodynamic-b) where both the polymer and PTX were dissolved in 
methanol and upon removing the solvent the crude complex was dissolved in water. This 
technique was preferred and continued to be used to ensure higher encapsulation efficiency 
based on the positive result obtained for the aqueous solubility of free PTX.  
Table 5.2: Thermodynamic and Kinetic Solubility of PTX in water 
 
5.2 Encapsulation of PTX in the polymeric micelles 
As discussed earlier in this chapter, the main aim of this study is to enhance the aqueous 
solubility of paclitaxel (PTX) within the self-assembled polymer structures. If successful, the 
system can then be studied as dual chemo and photodynamic anticancer therapy. 
It is expected that higher PTX loading will happen when there is enough hydrophobic space 
within the aggregated structures of each polymer; in other words, the loading capacity of PTX 






a 0.20 230 6.7 
b 0.75 230 25.2 
Kinetic 
1% DMSO 
0.1 237 3.34 
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the star copolymers are expected to aggregate at a higher loading of PTX when compared with 
the simpler HPGs.  
There are different methods commonly used for physical drug encapsulation in polymeric 
micelles such as dialysis, oil-water emulsion, and solvent evaporation, among others. In this 
study, the solvent evaporation method was used to evaluate the encapsulation of PTX within 
the polymeric micelles. The encapsulation procedure involved the dissolution of both the 
polymeric micelle and a large molar excess of the PTX in methanol. The two solutions were 
combined, and the solvent evaporated, resulting in a polymer-PTX co-precipitate. Water was 
added to the co-precipitate, to mimic physiological conditions, and the solution was filtered to 
remove any excess PTX loaded by the polymer by UV/Vis spectroscopy.  
5.3 Encapsulation results 
To be able to quantify the improvement in solubility of PTX when complexed to the polymeric 
micelles, it was important to record the UV/vis spectrum of the maximum concentration of 
PTX used for the encapsulation studies in water, without polymer present. From the absorbance 
at 230nm of PTX-loaded micelles, the concentration of the PTX loaded by each polymer was 
calculated using Beer-Lambert analysis and was compared to the maximum concentration of 
PTX determined for water (e.g. with no polymer present). The results showed that there was a 
slight increase in the solubility of PTX when encapsulated with different polymers, Table 5.4. 
The concentration of PTX loaded in the micelles of the star copolymers was slightly higher 
than its respective hyperbranched polymer as shown in Table 5.5. In addition, there was no 
noticeable difference in terms of increasing the solubility of PTX, between star copolymers 
and HPG polymers. Since the potency of PTX toward carcinoma cells is effective at a very low 
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concentration (in nM), the complexes (PTX loaded in polymer) were taken forward for toxicity 
studies.   
Table 5.3: Encapsulation result of PTX with star copolymers and HPGs 
 
5.4 In vitro study 
5.4.1 Control experiment to determine PTX toxicity to bladder cell line 
The cytotoxicity measurements were carried out by MTT assay in a bladder cell line (EJ) to 
evaluate the pharmacological efficiency of PTX and its nano-formulation. After 24 hours for 
the 24 nM and higher concentrations of PTX, the cell viability was less than 0.1%. After 48 
and 72 hours, cell viability was 0% for PTX concentration above 24 nM. This result confirms 
that PTX has a very high pharmacological potency. As such, only very low concentrations of 




[PTX] loaded in micelle 
µM 
S-TDHPP-HPG 40 
 S-TDHPP-PCL10-HPG35 43 
S-THPP-HPG 50 
S-THPP-PCL40-HPG60 60 
[PTX] in water: 25 µM 
Polymer concentration: 0.5 mg/mL 




Figure 5.3: PTX toxicity to bladder cell line at different incubation times.   
5.4.2 Polymer toxicity to bladder cell line 
Initially, the star copolymer (S-THPP1-PCL40-HPG60 31) was chosen to evaluate the polymer 
cytotoxicity in MTT assay using the bladder cell line. Different concentrations of the polymer, 
ranging from 2.4 to 2400 nM, were used but were shown not to be toxic (Figure 5.5).  
 

























Figure 5.5: Toxicity of different concentrations of the star copolymer to bladder cell line (No 
PTX encapsulation) 
Unfortunately, the cytotoxicity measurement of PTX-loaded star copolymers revealed no 
toxicity to the bladder cell line, indicating the PTX loaded in the micelle does not have potential 
to inhibit the cells anymore. 
 





































control average 2.4 nM 24 nM 240 nM 2400 nM
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The main reason as to why the PTX-loaded-polymeric systems did not show any toxicity could 
be either of the following; the release of PTX from the micelle is either very slow or it is not 
happening at all, or the PTX might have reacted with the polymer or with the solvent during 
encapsulation process, resulting in a loss of formation to its structure and subsequent loss of its 
pharmacological potency.  
To determine which effect was the cause, the release behaviour of PTX loaded in micelle was 
studied using two different buffer solutions (PH 7.4 and PH 5.0) at 37 oC. A relatively rapid 
release rate was observed using UV/vis spectroscopy (following the signal at 230 nm) after 24 
hours. Although this experiment confirmed that the PTX was not trapped in the micelle, it does 
not prove that the structure of the PTX had not been changed (it only confirmed that aromatic 
rings were present) and hence the first reason is not valid.  
The PTX exhibited a lot of weak electrophile sites (indicated with red arrows in Figure 5.7), 
which could be attacked easily with mild nucleophilic molecules.  If this was the case, the PTX 
structure would be changed and could be the reason why the toxicity of PTX-loaded-polymer 
had been lost. 
 
Figure 5.7: Structure of PTX indicating the electrophilic sites 
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The nucleophilic attack could happen via one of two possibilities; PTX could react with the 
OH groups of the polymers, or with the methanol used to encapsulate the drug within the 
polymer.  
 
Figure 5.8: Possible PTX-micelle formation 
Although the quantification of the PTX loaded in micelles was calculated using UV/Vis, this 
technique was not useful in determining the degradation of PTX. The reason could be because 
thr degradation of PTX occurs in the non-UV/vis sensitive sites which will not change the λmax 
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of PTX at 230 nm. However, this technique can be useful to validate one of the possibilities, 
that PTX had reacted with the micelle, by recording the UV/vis spectra of the extracted organic 
layer from the PTX-loaded micelle. Interestingly, the UV/vis spectra of the extracted organic 
layer confirmed the presence of aromatic resonances via the observation of an absorption 
maximum at 230 nm, indicating that the PTX was extracted in the organic layer.  
Another possibility that would explain this is that the PTX had reacted with the methanol during 
the encapsulation process and was extracted. In an attempt to prove this, a mass spectrum of 
the extracted PTX from the micelle was measured. The resulting spectra did not show the m/z 
peak for PTX at 877(M+ Na+1) but showed a molecular ion peak at 609 m/z instead. Also, there 
were some fragments below 609 m/z. Although the structure was unidentified, the results 
suggested that the PTX had degraded during the encapsulation process.  
Earlier, the high aqueous solubility of PTX using the solvent evaporation method was 
interpreted as methanol breaking the lattice of PTX and upon evaporation being converted to a 
more soluble allotrope. However, the true explanation may be due to methanol degradation of 
PTX, which could increase the polarity of the PTX compound. Therefore, the mass spectrum 
of PTX in methanol was measured for different reaction times to investigate the decomposition 
of PTX by the methanol, which can act as a nucleophile to attack any weak electrophile site in 
the PTX. The m/z obtained for PTX in methanol exhibited peaks for PTX at 875.6 and another 
peak at 907. These peaks are interpreted as follows: 
 907.7 - 875.6 = 32…. which is one methanol molecule attached to the PTX 
 875.6 - 22.9 (Na+) = 852.7 which is one proton less of the PTX. A proton loss would 
happen when a bond is broken by a nucleophile attack which would bond to the PTX.  
After leaving the PTX in methanol for a longer period, the mass spectrum showed a peak at 
907.7 and nothing observed at 875.6, inducing the covalent attachment of methanol to the PTX.  
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In addition, the PTX water solubility in methanol that has been stored for a long time was very 
high. The mass spectrum of PTX in DCM showed a peak at 876, for the PTX plus sodium ion, 
and another at 892, for the PTX plus potassium ion. This result confirms the fact that solvent 
which acts as a nucleophile can deform the PTX and reduce its potency as a chemotherapeutic 
drug. 
5.5 Encapsulation of PTX using kinetic method  
The solvent evaporation method caused degradation of the PTX. Therefore, PTX was 
encapsulated within the polymeric micelle using a kinetic encapsulation approach. PTX was 
dissolved in 100% DMSO to 16.4 mg/mL, then 10µLwas diluted further into 1mL DMSO to 
give a PTX stock solution of concentration 164 µg/mL. The PTX stock solution was further 
diluted to give concentrations from 0 to 40 µM and UV/vis spectroscopy analysis was used to 
give a Beer-Lambert Plot for PTX. In DMSO, PTX showed very good linearity with 
absorbance over the concentration range 0-40 µg/ml (Table 5.2). The absorption maximum 
(λmax) of PTX in 10% DMSO was observed at 242 nm which is 12 nm higher than the λmax 
observed for PTX in methanol (Figure 5.3).  
 
The kinetic encapsulation method was performed as follows: a polymer was dissolved directly 
in water to make the desired concentration (0.5 µg/mL), to the polymer solution PTX (DMSO 
Table 5.2: Characterisation of PTX in Water: DMSO  
Parameters PTX 
λmax (nm) 242 
Lambert-Beer’s law range (µM) 0.0 - 0.05 
Correlation coefficient (R2) 0.999 
Equation of line 20000X + 0.0048 
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solution) was added making 0.1% DMSO. The drug loading polymer solution was left stirring 
for a few hours to ensure the complete encapsulation, and then excess PTX was removed by 
filtration with a 0.2 µm syringe filter. UV/vis was used to evaluate the loading of PTX by 
observing the absorption of λmax at 230 nm, using water with 0.1% DMSO as the reference.  
Initially, the aqueous solubility of PTX in water using 0.1% DMSO was calculated from its 
absorbance in the UV/vis spectra and the extinction coefficient determined via Beer-Lambert. 
Low concentrations of hyperbranched polymers (HPGs) could increase the aqueous solubility 
of PTX according to their CMCs. The largest HPG, which aggregated at low concentration, 
increased the solubility of PTX by 429% (Table 5.3), whilst HPGs with Mn ranging from 10-
20 K Da encapsulated a similar amount of PTX.  













increase of  
PTX  
Water - - 0.1 7 0 
S-TDHPP-HPG 29 10K 350 0.31 21 200 
THPP-HPG 15K 300 0.35 24 243 
S-THPP-HPG 28 20K 150 0.34 23 229 
TDHPP-HPG 40K 80 0.54 37 429 
1Absorption of encapsulated PTX, dilution was required to get absorption below 1  
2Corrected concentration was determined by subtracting the concentration of PTX in water 
from the encapsulated PTX concentration 
3The increase in solubility was calculated  
 
The encapsulation of PTX within the star copolymer micelles could help determine where in 
the polymer the PTX is encapsulated. Star copolymers which had hydrophobic segments of 
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similar size but different sized hydrophilic segments (SPPCL35-HPG35 and SPPCL40-HPG60) 
were used to encapsulate excess PTX at a polymer concentration of 30 µg/mL. The star 
copolymer which had a higher size of hydrophilic segments (SPPCL40-HPG60) had lower CMC 
and, hence, enhanced the solubility of PTX the most.  
 
Copolymers which had a similar size of hydrophilic segments and different sized hydrophobic 
segments had encapsulated roughly similar amounts of PTX because they have similar CMC. 
This means that the encapsulation of the PTX occurs within the aggregated form of the star 
copolymer and is dependent on the CMC, rather than occurring in a specific segment of the 
polymer. 
5.6 Summary 
In this project, the chemotherputic molecule, paclitaxel, was encapsulated within the porphyrin 
cored polymers via hydrophobic interaction. During the encapsulation process, where the drug 
molecule was dissolved in methanol and mixed with methanol solution of the polymer to form 
the complex, the potency of the drug molecue was lost when it was tested in MTT assay using 
MCF-7 cell line. After further investigation, it turns out that there are a lot of  electrophilic sites 
in the drug that could be reacted with a nuclophilic solvent and henc using methanol was not 









% increase of PTX 
SPPCL10-HBP35 200 0.22 15 113 
SPPCL35-HBP35 170 0.24 16 132 
SPPCL40-HBP60 50 0.66 30 328 
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within the polymer without harming the drug. However, the potency of the complexes could 














6.0 Conclusion and Further-work 
In this project, we synthesised successfully macromolecular carriers with the ability to host 
macromolecular guest via one pot procedure. The synthesis of the macromolecule host started 
from using trimethylol propane as a multifunctional core followed by two subsequent ring 
opening polymerization steps of caprolactone and glycidol, respectively. Three star copolymers 
(SPCL-HPGs) were prepared with different chain length and similar size of the capping group 
(SPCL15-HPG90, SPCL35-HPG90 and SPCL60-HPG90) in order to study the effect of the chain 
length upon encapsulating large molecule. A hydrophilic HPG polymer was synthesised as the 
only control system of our proposed drug delivery system. The polymers (star copolymer and 
HPG) do form aggregates in water, this was confirmed using pyrene as probe for determining 
the CMC and by DLS which showed their hydrodynamic diameter size (100-200 nm). Having 
synthesised successfully the proposed drug delivery system and the control, a model 
macromolecular guest, a synthetic mimic of hemoglobin (TAPP-HBP 15), was synthesised 
successfully with average molecular weight of 18K Da. Upon encapsulation, significant 
amount of the guest (1.7 x 10-5 to 3.3 x 10-5 M) was loaded within the star copolymers than it 
was for the control system (3.6 x 10-6 M). The poor encapsulation of the guest within the control 
(HPG) was thought to be related to the aggregated structure of the polymer; HPG does not have 
a hydrophobic segment that can form micelle structure with large hydrophobic domain to 
encapsulate great amount of the guest as it was seen for the star copolymers. So, the star 
copolymers was deemed to be a solution for improving the aqueous solubility of large 
molecule. This delivery system could be a suitable carrier for peptide or other large 
biomolecules only if the chain of its hydrophobic segments been functionalised. This could be 
achieved by synthesising a functionalised caprolactone monomer and then synthesising the star 
copolymer in the same manner as our delivery system.  
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The second part of the project discussed the synthesis of star copolymers with porphyrin core 
for Photodynamic therapy (PDT). Porphyrins and their derivatives have been used extensively 
in PDT. In this study, the solubility of porphyrins in aqueous solution was enhanced 
significantly via covalent incorporation within aggregated water-soluble polymers (porphyrin 
cored star copolymers, and porphyrin cored HPG). Two porphyrin molecules with hydroxyl 
end group were selected as a core these are: tetrakis(3,5-dihydroxyphenyl) porphyrin) 
(TDHPP), and tetrakis(4-(hydroxyphenyl)porphyrin (THPP). However, TDHPP and THPP 
were very unreactive initiators for ring opening polymerization of caprolactone until a spacer 
was added. Thus, two star copolymers were synthesised from spacer-porphyrin (S-THPP-PCL-
HPG) and S-TDHPP-PCL-HBP). The control (porphyrin-HPG) were synthesised from 
porphyrins with and without spacer units. The particle size of all the aggregated polymers was 
between 100-200 nm determined by DLS. The cytotoxicity and phototoxicty of  the star 
copolymers  (compound 31 and 33)were tested initially via SRB assay using MCF-7 cell line. 
The result showed that both of the polymers, compound 31 and 33, exhibited negligaible 
toxicity at concentration of 400 and 900 µM. The phototoxicity of these compounds were 
obvious at 14 and 50 µM, respectively. The cytotocity and phototoxicty of all the porphyrin 
cored polymers were inistigated further for their PDT behaviour via a simple MTT assay, using 
the EJ (bladder carcinoma) cancer cell line. The relative viability of the polymers and its 
controls in the dark were higher than 0.8 at 100µM except the THPP-HPG polymer which had 
a viability 0.2. Under light irradiation (10 mW/cm2), significant toxicity was observed at 1 µM 
for the free THPP and at 10 µM for the free TDHPP porphyrin. While phototoxicity of the 
polymers, considerable cell death was obvious at polymers concentration of 10 µM for the 
THPP cored polymers except the star copolymer, which did not show any significant toxicity 
at this concentration. The phototoxicity of TDHPP cored polymers were significant for 
TDHPP-HPG and S-TDHPP-HPG at 100 µM for and poor for the star copolymer at same 
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concentration. The intracellular localisation of the molecules porphyrin cored polymers into EJ 
cells was imaged by confocal microscopy. Both of the free porphyrin (THPP and TDHPP) 
molecules diffused within the cell at a concentration of  10 µM.  Porphyrin cored HPG 
polymers also diffused within the cells but as the spacer was added the diffused fluorescence 
decreases. The porphyrin-PCL-HPGs star copolymers showed no diffusion into the cells. Thus, 
porphyrin-cored HPG polymers were deemed to be promising photosensitizers for 
photodynamic therapy (PDT) rather than the star copolymers. Other photosensitizers (such as 
phthalocyanine and chlorine) could be functionalised with nucleophilic end group and used as 
core for ROP of glycidol for effective PDT. These compounds as effective photosensitizer 
could then be investigated further using different cell lines and assay. In vivo study would be 
needed to confirm the compounds effectiveness in PDT. 
In the final part of this project, porphyrin cored polymers were used to encapsulate 
chemoterputic drug molecule, paclitaxel, via hydrophobic interaction. The encapsulation 
method used initially were seen to be great but when the potency of  the complex (durg-loadd 
in polymer) was not observed when  it was tested against breast cancer cell line. After further 
investigation, it turns out that the drug has lost it potency during the encapsulation process 
(methanol reacted with the paclitaxel). Therefore 0.1% of DMSO was used to aid the 
encapsulation of the paclitaxel within the polymer without harming the drug. However, the 












7.1 General consideration 
7.1.1 Reagents, solvents and general equipment 
All reagents and solvents were obtained from commercial sources (primarily Sigma- Aldrich) 
and were used without further purification unless otherwise. Dry solvents were obtained from 
the University of Sheffield Chemistry Department Grubbs solvent dispensing system. All 
glassware was cleaned and flame-dried under ambient conditions.  
7.1.2 Nuclear magnetic resonance spectroscopy  
1H NMR spectra were performed at 400 MHz using a Bruker ‘AV3HD-400’ spectrometer 
equipped with a 5mm probe. 13C NMR was performed at 100 MHz using a Bruker ‘AV-400’ 
spectrometer equipped with a 5mm BBO BB-1H probe. Chemical shifts are reported in parts 
per million (ppm) from trimethylsilane. All samples were prepared using deuterated solvents 
supplied by Sigma Aldrich. Resonance were analysed using Bruker TopSpin 3.0 NMR 
software. Impurities were assigned using ‘NMR Chemical Shifts of Common Laboratory 
Solvents as Trace Impurities’. 
7.1.3 UV-Vis Spectroscopy  
The ultraviolet absorbance characteristic of materials was recorded on an Analytic Jena AG 
Specord s600 uv/vis spectrometer and analyzed using its attached Software (WinASPECT). 
Solutions were made up in an appropriate solvent and the instrument was calibrated with pure 
solvent before use.  
7.1.4 IR Spectroscopy  
Infra-Red (IR) spectra were recorded using a Perkin Elmer Paragon Spectrum 100 FT-IR 
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spectrophotometer with νmax in cm
-1. Samples were recorded neat (without using Nujol or KBr) 
using sodium chloride plates and recorded as a thin film subsequent to solvent evaporation. 
7.1.5 Thermal analysis  
Melting point characteristic of materials was recorded on 
 
7.2 Synthesis of porphyrin molecules 
7.2.1 5,10,15,20-Tetrakis(4-hydroxyphenyl)-21H,23H-porphine (THPP 12) 
 
 
Freshly distilled pyrrole (4.17 ml, 60 mmol) and 4-hydroxy benzaldehyde (7.3 g, 60 mmol) 
were added to propionic acid (300 ml) that was maintained under reflux. The mixture was 
refluxed for 1 hour, allowed to cool to room temperature and placed for 1 hour at −5 °C and 
the filtered cake was washed thoroughly with the mixture of propionic acid and ethanol (1:1), 
and CHCl3, respectively. 
Yield: 1.32 g, 13%. 1HNMR (400 MHz, (CD3)2SO): δH 9.99 (s, 4H, phenolic p-OH), 8.85 (s, 
8H, pyrrolic-CH), 7.97 (d, 8H, phenolic m-CH), 7.18 (d, 8H, phenolic o-CH), −2.92 (s, 2H, 
NH-pyrrole); 13C NMR (400 MHz, CD3OD): δC 156.5, 143.7, 120.0, 114.4, 101.8; IR (cm
-1) 
3431 (OH); UV Absorbance (MeOH) λmax (nm) = 418.5, 516, 554, 649; (M+H)
+ (ESI-MS) = 
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679 ( calculated 679 gmol-1). 
7.2.2 Tetrakis (3, 5-dimethoxyphenyl)-21H, 23H-porphyrin (TDMPP 18) 
 
Freshly distilled pyrrole (4.17 ml, 60 mmol) and 3, 5- dimethoxybenzaldehyde (10.0 g, 60 
mmol) were added to propionic acid (300 ml). The mixture was maintained under reflux for 30 
minutes, allowed to cool to room temperature and collected via vacuum filtration. The obtained 
product was washed thoroughly with methanol before being oven dried at 40 0C to give purple 
crystals. 
Yield: 2.9 g 23%, 1H NMR (400 MHz, CDCl3): δH 8.94 (s, 8H, pyrrolic β-H), 7.43 (s, 8H, 
phenolic o-CH), 6.95 (s, 4H, phenolic p-CH), 3.99 (s, 24H, phenylic m-CH3), -2.89 (s, 2H, 
NH); 13C NMR δc (400 MHz, CDCl3): δ 158.9, 144.0, 119.8, 113.8, 100.2, 26.9; IR: vmax/cm
-1 
1150 (OMe); UV Absorbance (CH2Cl2) λmax (nm)= 420.5, 513, 548, 585.5, 643.5;( M+H)
+ 
(ESI-MS) = 855 (calculated 855 gmol-1). 
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7.2.3 Tetrakis (3, 5-dihydroxyphenyl)-21H, 23H-porphyrin (TDHPP 13) 
 
A round bottomed flask was bulls charge with 5, 10, 15, 20- tetrakis (3,5-dimethoxyphenyl)-
porphyrin 18  (1g, 1.17 mmol), anhydrous dichloromethane (40 ml) and flashed with nitrogen. 
BBr3 (3 ml, 31.6 mmol) was added via syringe and the reaction mixture was stirred gently 
under nitrogen at room temperature for 5 hours. The reaction was then quenched carefully with 
distilled water (1.5ml, 0.08mol) and stirred for a further 20 mins. The crude mixture was then 
neutralised with a saturated solution of sodium hydrogen carbonate and extracted with ethyl 
acetate.  
Yield: 0.9 g, 90%; 1H NMR (400 MHz, CD3OD) δH 9.04 (d, 8H, pyrrolic β-H), 7.52 (d, 8H, 
phenylic o-CH), 6.96 (t, 4H, phenylic p-CH), 4.91 (s, 8H, phenylic m-OH), -2.89 (s, 2H, NH); 
13C NMR (400 MHz, CD3OD) δC 156.5, 143.7, 120.0, 114.4, 101.8; IR (cm
-1) 3431 (OH); UV 
Absorbance (MeOH) λmax (nm) = 416.5, 512.5, 547.5, 588, 644.5; (M+H)
+ (ESI-MS) = 743 
(calculated 743 gmol-1). 
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7.3 Synthesis of porphyrin initiator  
7.3.1 Spacer-porphyrin (S-TDHPP 27) 
 
5,10,15,20-Tetrakis(3,5-dihydroxyphenyl)-21H,23H-porphyrin (200 mg, 0.269 mmol), K2CO3 
(906 mg, 6.4 mmol, 24 equiv.), and 18-crown-6 (20 mg) were added to 60 mL of 
dimethylformamide (DMF). 1,3-Bromopropanol (582 mg, 4.18 mmol, 16 equiv) was added 
and the reaction was stirred vigorously under reflux overnight followed by TLC analysis. The 
DMF was evaporated under reduced presuure and the reaction mixture was dissolved in 200 
mL of THF and extracted three times with water (100 mL) with the addition of brine to obtain 
phase separation. The solvents were evaporated, and the crude product was dissolved in a small 
amount of THF, precipitated in cold diethyl ether, filtered, and dried to yield S-TDHPP 27 a 
purple solid. 
Yield:170 mg, 86%, 1H NMR (400 MHz, DMSO-d6): δH 8.90 (d, 8H, pyrrolic β-H), 7.32 (d, 
8H, phenylic o-CH), 6.97 (t, 4H, phenylic p-CH), 4.58 (s, 8H, phenylic m-OH), 4.22 (t, 8H, -
O-CH2-CH2), 3.58 (t, 8H, -CH2-OH), 2.67 (m, 8H, -CH2-CH2-CH2-), -3.01 (s, 2H, NH); 
13C 
NMR(400 MHz, DMSO-d6): δC 158.4, 135.5, 135.4, 134.6, 119.5, 112.0, 56.87, 54.01, and 
31.62; ESI-MS (M+H)+ = 1207 ( calculated 1207). 
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7.3.2 Spacer-porphyrin S-THPP 26 
 
5,10,15,20-Tetrakis(4-hydroxyphenyl)- 21H,23H-porphyrin (177 mg, 0.261 mmol), K2CO3 
(453 mg, 3.13 mmol, 12 equiv), and 18-crown-6 (10 mg) were added to 30 mL of 
dimethylformamide (DMF). 1,3-Bromopropanol (291 mg, 2.09 mmol, 8 equiv) was added and 
the reaction was stirred vigorously under reflux overnight followed by TLC analysis. The DMF 
was evaporated and the reaction mixture was dissolved in 200 mL of THF and extracted three 
times with water (100 mL) with the addition of brine (30 mL) to obtain phase separation. The 
solvents were evaporated, and the crude product was dissolved in a small amount of THF, 
precipitated in cold diethyl ether, filtered, and dried to yield S-THPP 26 a purple solid.  
Yield: 150 mg, 85%, 1H NMR (400 MHz DMSO-d6): δH 8.85(s, 8H, β-Pyrrole), 7.97(d, 8H, 
phenylic m-CH), 7.18(d, 8H, , phenylic o-CH), 4.58 (s, 4H, phenylic m-OH), 4.20 (t, 8H, -O-
CH2-CH2), 3.63 (t, 8H, -CH2-OH), 2.47 (m, 8H, -CH2-CH2-CH2-), -3.01 (s, 2H, NH); 
13C NMR 
(400 MHz DMSO-d6); δc 158.4 (ArC- O), 135.5 (p-ArC), 135.4 (m-ArC), 134.6 (pyrrole C), 
119.5 (meso-porphyrin C), 112.0 (o-ArC), 56.9 (-O-CH2- CH2), 54.0 (-CH2-OH), and 31.6 (-
CH2-CH2-CH2-); (M+H)




7.4 Synthesis of TAPP cored poly (3, 5-diacetoxybenzoic acid) 15 
7.4.1 Synthesis of 3, 5-diacetoxybenzoic acid (13) 
 
A round bottomed flask was charged with acetic anhydride (20 ml) and 3, 5- dihydroxybenzoic 
acid (5.0 g, 50 mmol). The reaction mixture was stirred for 10 minutes and sulfuric acid (50 
ml) was added dropwise. The flask was then left to cool for 30 minutes. Distilled water (100 
ml) was added into the flask to remove the excess acetic anhydride and acetic acid by-products. 
The crude product then precipitated a white crystalline solid. After 2 hours of stirring, the 
product was isolated using gravity filtration and thoroughly washed with distilled water (2 x 
30 ml).  
Yield 10.5 g, 89 %; 1H NMR (400 MHz, CDCl3) δ 10.15 (br, s, 1H, -COOH), 7.75 (d, J 2.2 
Hz, 2H, Ar o-CH), 7.24 (t, J 2.2 Hz, 1H, Ar-p-CH), 2.34 (s, 6H, -CH3); 
13C NMR (400 MHz; 
CDCl3) δ 170.2 (COOH), 168.9 (C=O), 151.1 (m-Ar), 131.4 (i-Ar), 121.3 (p-Ar), 120.9 (o-Ar), 
21.0 (CH3); IR: νmax/cm-1 (thin film, NaCl plates) 2400-3250, 1771 (COOMe), 1692 
(COOH), 1597 (Ar C=C); MH+ (ESI-MS) = 237( calculated 237); MP 160-164 0C. 
7.4.2 Synthesis of 4-acetoxybenzaldehyde (7) 
 
A round bottomed flask was bulls charge with 4-hydroxybenzaldehyde (10 g, 84 mmol), 
triethylamine (15 ml, 108 mmol) and anhydrous THF (300 ml). The mixture was then stirred 
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under nitrogen and then acetyl chloride (15 ml, 211 mmol) was added dropwise via a syringe. 
The mixture was then stirred for a further 30 minutes at ambient temperature. The reaction 
mixture was then filtered and the brown filtrate was collected and the solvent was reduced via 
rotary evaporation to form brown oil. The product was dissolved in dichloromethane (200 ml) 
and washed with a saturated sodium hydrogen carbonate solution (300 mL) and distilled water 
(200 mL). The organic layer was collected and dried over magnesium sulfate to yield the crude 
product. 
Yield: 8.2 g, 60 %; 1H NMR (400 MHz, CDCl3) 9.95 (s, 1H, COH), 7.95 (d, 2H, Ar-H), 7.25 
(d, 2H, Ar-H), 2.35 (s, 3H, CH3); 
13C NMR (400 MHz; CDCl3) 190.9, 168.5, 155.0, 133.9, 
131.0, 122.35, 21.0; IR: νmax/cm
-1 (thin film, NaCl plates) 1756 (C=O), 1280 (C-O); M+H+ 
(ESI-MS) =163 (calculated 164). 
7.5 Synthesis of tetrakis (4-diacetoxyphenyl)-21H, 23H-porphyrin (TAPP 12) 
 
Freshly distilled pyrrole (2.8 mL, 40 mmol) and 4-acetoxybenzaldehyde 7 (6.5 g, 40 mmol) 
were added to refluxing propionic acid (200 mL). The mixture was maintained under reflux for 
30 minutes and then cooled to room temperature. It was then filtered and washed with methanol 
until colourless. 
Yield, 22 %, 1H NMR (400 MHz, CDCl3) 8.90 (d, 8H, pyrrolic β-H), 8.25 (d, J 7.8 Hz, 8H, 
phenolic o-C-H), 7.50 (d, J 7.8Hz, 8H, phenolic m-CH), 2.50 (s, 12H, CH3), -2.83 (s, 2H, N-
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H); 13C NMR (400 MHz; CDCl3) 169.5, 150.5, 139.5, 135.4, 131.1, 119.7, 119.2, 21.2; IR: 
νmax/cm-1 1750 (C=O); λmax (CH2Cl2) (nm): 418, 515, 549, 590, 643; M+H
+ (ES-MS) = 847 
(calculated 847). 
7.6 Synthesis of TAPP cored poly (3, 5-diacetoxybenzoic acid) (15) 
 
 
Tetrakis (4-acetoxyphenyl)-porphyrin 12 (0.3 g, 0.35 mol), 3,5-diacetoxybenzoic acid 13 (6.8 
g, 28.56 mmol) and diphenyl ether (2.0 g) were added to a round bottomed flask fitted with 
distillation kit. The reaction mixture was degassed thoroughly and flushed with nitrogen and 
then heated to 225 °C. After 45 minutes, the temperature was reduced to 180 °C, and the 
reaction was placed under vacuum for 4 hours. The mixture was then dissolved in THF and 
precipitated into methanol (600 ml). The brown solid was then filtered and washed using cold 
methanol. The crude polymer was then loaded onto a Biobead column to remove any unreacted 
porphyrin. 
1H NMR (400 MHz, CDCl3) δ 8.95 (s, 8H, pyrrolic β-H), 8.26 (d, J 8.50 Hz, 8H, phenylic o-
CH), δ 8.04-7.93 (m, [polymer] Ar-p-CH), 7.52 (d, J 8.50 Hz, 8H, phenylic m-CH), 7.45-7.19 
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(br, 1H [polymer] Ar-o-CH), 2.36 (s, 24H, CH3), -2.81 (s, 2H, NH); 13C NMR (400 MHz; 
CDCl3) 167.7, 163.5, 151.6, 150.4, 132.9, 131.5, 130.2, 129.5, 122.4, 121.9, 120.5, 23.0; λmax 
(CH2Cl2)/nm 418.5, 518, 553, 596, 644; IR: νmax/cm
-1 1752 (C=O); GPC (THF) Mn, 18,600 
Da, PDI 2.6. 
7.7 General procedure for synthesis of hyperbranched polyglycerol 
 
The hydroxyl functional core was added to diethylene glycol dimethyl ether in a round bottom 
flask fitted with a condenser under nitrogen atmosphere. The solution was stirred at 50 °C until 
the core was fully dissolved. A base such as potassium methoxide was added to the stirring 
solution and the temperature was raised to 90 °C for 90 minutes. Glycidol was then added 
dropwise via a syringe pump and the reaction was left for a further 5 hours. The reaction 
mixture was cooled to room temperature and the solvent was disposed of. A minimum amount 
of methanol was added to the product and the mixture left to stir until it had all dissolved. In a 
separate beaker cold acetone was stirred and then the methanol solution of the product was 
added to the acetone in a drop wise fashion . Once the addition was complete, the mixture was 
covered with tin foil and left stirring for 1 hour before disposing of the acetone. Cold acetone 
was added to the product again before covering with tin foil and stirring for another hour. The 
acetone was disposed of to yield a yellow product which was dried overnight in a vacuum to 
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give hyperbranched poly glycerol as a deep yellow extremely viscous liquid. 
7.7.1 Synthesis of trimethylolpropane (TMP) core hyperbranched polyglycerol  
 
General procedure 6.4.1 was used to synthesize the polymer. The reaction used 
trimethylolpropane (0.01g, 0.07 mmol), diethylene glycol dimethyl ether (20 ml), potassium 
methoxide (0.05 g, 0.03 mmol) and glycidol (1.5g, 20.27 mmol). 
1H NMR (400 MHz, D2O); δH 4.17-3.22 (br m OH + CH + CH2), 1.17(m, CH2);
 13C NMR (400 
MHz, D2O) δC 63.1, 71.2, 78.9;  IR (cm
-1): 3360 (OH), 2875 (CH2, CH), 1335 (C-O-C); GPC 
(aq.) Mn 18K Da, PDI 3.6.  
7.7.2 Synthesis of porphyrin core hyperbranched polyglycerol  
7.7.2.1 THPP to glycidol molar ratio per OH group 1:50 
 
General procedure 6.4.1 was used to synthesize the polymer. The reaction used TDHPP 
porphyrin (0.1g, 0.15 mmol), diethylene glycol dimethyl ether (20 ml), potassium methoxide 
(0.041 g, 0.58 mmol) and glycidol (2.22g, 30.0mmol). 
1H NMR (400 MHz, D2O) δH: 9.81, 8.45, 4.11-3.20 (br m OH + CH + CH2); 
13C NMR (400 
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MHz, D2O) δC 62.5, 70.6, 79.1;  IR (cm
-1): 3270 (OH), 2916 (CH2, CH), 1636 (C=O), 1327 
(C-O-C), 1051 (C-O); Mn 14K Da, PDI 1.5. 
7.7.2.2 TDHPP to glycidol molar ratio per OH group 1:50 
 
General procedure 6.4.1 was used to synthesize the polymer. The reaction used TDHPP 
porphyrin (0.1g, 0.13 mmol), diethylene glycol dimethyl ether (20 ml), potassium methoxide 
(0.08 g, 1.07 mmol) and glycidol (3.84g, 52.0mmol). 
1H NMR (400 MHz, D2O) δH : 9.89, 8.55, 4.08-3.20 (br m OH + CH + CH2); 
13C NMR (400 
MHz, D2O) δC 62.7, 70.3, 78.1; IR (cm
-1): 3342 (OH), 2871 (CH2, CH), 1626 (C=O), 1330 (C-
O-C), 1062 (C-O) ); GPC (aq.) Mn 14K Da, PDI 1.5. 
7.7.3 Synthesis of (porphyrin with spacer) core hyperbranched polyglycerol  




General procedure 6.4.1 was used to synthesize the polymer. The reaction used TDHPP 
porphyrin (0.1g, 0.11 mmol), diethylene glycol dimethyl ether (20 ml), potassium methoxide 
(0.031 g, 0.43 mmol) and glycidol (1.63g, 22.0mmol). 
1H NMR (400 MHz, D2O) δH : 9.87, 8.50, 4.08-3.21 (br m OH + CH + CH2); 
13C NMR (400 
MHz, D2O) δC 62.3, 70.0, 78.8;  IR (cm
-1) : 3391 (OH), 2873 (CH2, CH), 1641 (C=O), 1327(C-
O-C), 1042 (C-O); GPC (aq.) Mn 20K Da, PDI 2.3. 
7.7.3.2 S-TDHPP to glycidol molar ratio per OH group 1:50 
 
 
General procedure 6.4.1 was used to synthesize the polymer. The reaction used S-TDHPP 
porphyrin (0.1g, 0.08 mmol), diethylene glycol dimethyl ether (20 ml), potassium methoxide 
(0.046 g, 0.6 mmol) and glycidol (2.36g, 32.0mmol). 
1H NMR (400 MHZ, D2O) δH : 9.83, 8.52, 4.05-3.22 (br m OH + CH + CH2);
 13C NMR (400 
MHz, D2O) δC 61.3, 70.2, 78.7; IR (cm
-1) : 3351 (OH), 2867(CH2, CH), 1649 (C=O), 1329 (C-




7.8 General Procedure for Synthesis of Amphiphilic Copolymers Based On 
Poly(Caprolactone) and Polyglycerols 
Poly (Ɛ-caprolactone)-block-polyglycerols (PCL-HPG) copolymers were synthesized in two 
steps. Initially PCL was synthesized by controlled ring-opening polymerization of Ɛ-
caprolactone (Ɛ-CL) using initiator (such as alcohol), in the presence of stannous octoate 
(SnOct2). The molecular weight of PCL depended on the molar ratio of Ɛ-CL to hydroxyl 
group/s in the initiator. The polymerization procedure was described as follows: The core and 
Ɛ-CL were quickly added into a dry polymerization flask under nitrogen atmosphere. Tin (II) 
2-ethyl hexanoate (0.05 % w/w) was added to the mixture, then the reaction flask was degassed 
three times and stirred under nitrogen for 24 hours at 130 °C. The second step was started after 
the withdrawal of small sample of the reaction flask for GPC analysis. Then, the temperature 
was decreased to 90 0C followed by the addition of 1,4-dioxane and a base such as potassium 
methoxide. The reaction flask was then degassed with at least three cycles followed by the slow 
addition of glycidols. Stirring the reaction mixture for several hours after the complete addition, 
the mixture was cooled to room temperature and then the solvent was evaporated. The 
minimum amount of methanol was added to the product and the residue was filtered. The 
filtrate was then added to a beaker of acetone drop-wise. Once the addition was complete, the 
mixture was covered with tin foil and left to stir for 1 hour. The solvent was disposed of and 
the product dried to give star poly (caprolactone) block hyperbranched polyglycerol.  
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The general procedure was used to synthesis the polymer. The reaction used TMP (60.0 mg, 
0.46 mmol), CL (2.3 g, 20.7 mmol), Sn(Oct)2 (10mg) and glycidol (3.1 g, 40.4 mmol). 
Yield: 3.6 g, 65%; 1H NMR (400 MHz, D2O) δH 2.33 (H, m, α-CH2), 1.66 (m, β and δ-CH2), 
1.39 (m, γ-CH2) 3.20-4.25 (br m OH + CH + CH2);
 13C NMR (400 MHz, D2O) δC 173.8, 70.7, 
64.2, 34.3, 28.4, 25.4, 24.6; IR (cm-1): 3277 (OH), 2861 (CH sp3), 1724 (C=O stretch), 1644, 
1335 (C-O-C stretch), 1060 (C-O stretch); GPC (aq.) Mn 4.8K Da, PDI 1.9.  
TMP1PCL35-HPG30 
General procedure was used to synthesis the polymer. The reaction used TMP (0.1g, 0.92 
mmol), CL (4.18ml, 36.68mmol), Sn(Oct)2 (10mg) and glycidol (6.8g, 92.0 mmol).  
Yield: 10.3 g, 60%; 1H NMR (400 MHz, D2O) δH 2.32 (H, m, α-CH2), 1.66 (m, β and δ-CH2), 
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1.38 (m, γ-CH2) 3.20-4.23 (br m OH + CH + CH2);
 13C NMR (400 MHz, D2O) δC 173.4, 70.5, 
65.2, 34.3, 28.1, 25.1, 24.7; IR (cm-1): 3279 (OH), 2851 (CH sp3), 1728 (C=O stretch), 1650, 
1332 (C-O-C stretch), 1060 (C-O stretch); GPC (aq.) Mn 4.5K Da, PDI 2.2. 
7.8.1.1 TMP1PCL60-HPG30 
General procedure was used to synthesis the polymer. The reaction used TMP (60.0 mg, 0.46 
mmol), CL (9.4 g, 82.8 mmol), Sn(Oct)2 (10mg) and glycidol (3.1 g, 40.4 mmol). 
Yield: 9.1 g, 72%; 1H NMR (400 MHz, D2O) δH 2.33 (H, m, α-CH2), 1.64 (m, β and δ-CH2), 
1.37 (m, γ-CH2) 3.20-4.21 (br m OH + CH + CH2);
 13C NMR (400 MHz, D2O) δC 173.5, 70.9, 
64.0, 34.6, 28.4, 25.1, 24.2; IR (cm-1): 3260 (OH), 2859 (CH sp3), 1729 (C=O stretch), 1645, 
1332 (C-O-C stretch), 1064 (C-O stretch); GPC (aq.) Mn 4.8K Da, PDI 1.6. 
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7.8.2 Synthesis of porphyrin cored star poly (caprolactone)-b-hyperbranched  
7.8.2.1 Synthesis of TDHPP-PCL-HPG 
 
S-TDHPP1-PCL10-HPG35 
General procedure was used to synthesis the polymer. The reaction used S-TDHPP (132mg, 
0.11mmol), CL (1.0 g, 8.7mmol), Sn(Oct)2 (10 mg) and glycidol (1.13g, 15.4mmol).  
Yield: 0.74 g, 65%; 1H NMR (400 MHz, D2O) δH 2.33 (H, m, α-CH2), 1.66 (m, β and δ-CH2), 
1.39 (m, γ-CH2) 3.20-4.23 (br m OH + CH + CH2), δH 8.32 (br d, aromatic H), 7.73 (br s, 
aromatic H), 7.35(br s, aromatic H); 13C NMR (400 MHz, D2O) δC 173.6, 70.3, 64.2, 34.3, 28.7, 
25.4, 24.8; IR (cm-1): 3271 (OH), 2860 (CH sp3), 1720 (C=O stretch), 1652, 1331 (C-O-C 




The general procedure was used to synthesis the polymer. The reaction used OH-Prop-THPP 
(132mg, 0.11mmol), CL (4.0 g, 35.2mmol), Sn(Oct)2 (10 mg) and glycidol (1.13g, 15.4mmol). 
Yield: 0.68 g, 60%;  1H NMR (400 MHz, D2O) δH 2.32 (H, m, α-CH2), 1.65 (m, β and δ-CH2), 
1.39 (m, γ-CH2) 3.20-4.21 (br m OH + CH + CH2), δH 8.32 (br d, aromatic H), 7.73 (br s, 
aromatic H), 7.37(br s, aromatic H); 13C NMR (400 MHz, D2O) δC 173.1, 71.3, 64.1, 34.6, 28.7, 
25.5, 24.8; IR (cm-1): 3271 (OH), 2860 (CH sp3), 1725 (C=O stretch), 1651, 1331 (C-O-C 
stretch), 1061 (C-O stretch); GPC (aq.) Mn 40K Da, PDI 1.1. 
7.8.2.2 Synthesis of THPP-PCL-HPG 
S-THPP1-PCL40-HPG60 
 
The general procedure was used to synthesis the polymer. The reaction used OH-Prop-THPP 
(100mg, 0.11mmol), CL (2.0 g, 17.5mmol), Sn(Oct)2 (10 mg) and glycidol (1.95g, 26.4mmol).  
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Yield: 1.5g, 72%; 1H NMR (400 MHz, D2O) δH 2.33 (H, m, α-CH2), 1.64 (m, β and δ-CH2), 
1.39 (m, γ-CH2) 3.20-4.23 (br m OH + CH + CH2), δH 8.32 (br d, aromatic H), 7.73 (br s, 
aromatic H), 7.37(br s, aromatic H); 13C NMR (400 MHz, D2O) δC 173.0, 71.1, 64.0, 34.5, 28.8, 
25.4, 24.8; IR (cm-1): 3270 (OH), 2862 (CH sp3), 1726 (C=O stretch), 1651, 1335 (C-O-C 
stretch), 1059 (C-O stretch); GPC (aq.) Mn 22K Da, PDI 1.0. 
7.9 Critical aggregation concentration (CAC) 
Pyrene was used as a hydrophobic fluorescent probe. Aliquots of pyrene solutions (6×10-6 M 
in acetone, 1ml) were added to the vials and the acetone was allowed to evaporate. Aqueous 
polymer solutions at different concentrations were then added to the vials which containing 
pyrene residue. The solutions was left at room temperature for 24 hours to reach the 
solubilisation equilibriums of pyrene in the aqueous phase. Excitation was carried at 340nm 
and the emission spectra were recorded over a range of 350 to 600 nm. Both excitation and 
emission silt widths were 5 nm. From the pyrene emission spectra, the intensities (peak height) 
ratios (I3/I1) of the third band to the first band were analysed as a function of the polymer 
concentrations. A CMC value was determined from the interaction of the tangent to the curve 
at the inflection with the horizontal tangent through the point at low concentration. 
7.10 Cell Culture  
EJ (bladder carcinoma) cells were purchased from American Type Culture Collection–LGC 
partnership (Teddington, UK) and used within 20 passages of purchase. Cells were cultured 
using Dulbecco’s modified Eagles Medium (DMEM) (Lonza, Cambridge, UK) with 10% fetal 
calf serum (FCS) (Lonza, Cambridge UK) and cultured in an incubator (37 0C, 5 % CO2). The 
cells were passaged when 70 – 80% confluency was reached and regularly checked for 
mycoplasma contamination. Stock solutions of compounds were stored in deionised water, or 




EJ cells were seeded on sterile cover slips (22 x 22 mm) in 6 well dishes at a density it of 
150,000/well and incubated overnight. Staining solutions of the desired compound were made 
by dilution into culture media (10 µM) and added to the cells for 24 hours. Once incubation 
had taken place the cells were washed (PBS) and fixed (4% paraformaldehyde solution in PBS, 
4 0C, 20 minutes) before being washed again (PBS) and mounted (IMMU-MOUNT, Life 
Technologies Ltd, Paisley, UK). 
The slides were imaged by confocal microscopy (Inverted Zeiss LSM 510 NLO microscope) 
using a 60 x lens with activation by helium-neon laser (λ = 633 nm). Emission was registered 
in the region 650-710 nm. 
7.10.2 Light and dark toxicity – MTT assay 
96 Well-plates were seeded with EJ cells at 3000/well and incubated overnight. The wells were 
treated with compound (1 – 100 µM) or control (DMSO for porphyrin) and incubated for 24 
hours. The media was removed and 40 µl/well PBS was added to each well.  For light toxicity 
experiments the plate was placed in a foil lined box, 6 cm below the light source (10 minutes, 
450 nm/ 630 nm LED array at 4.2 mW 450 nm light and 4.85 mW 630 nm light) while dark 
toxicity plates were kept in the dark. Following light treatment, media was added to (DMEM, 
10 % FCS, 200 µl/well) and the plates were placed in the incubator. Following 24-hour 
incubation thiazoyl blue (MTT) solution was added to each well (25 μL, 3 mg ml-1 in PBS). 
After 3 hours incubation, the media and MTT solution was removed from each well and DMSO 
was added (150 μl/well) and crystals dissolved. The optical density of wells at 540 nm was 
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